



**Malawi**

**Country Operational Plan**

**FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		2,300,000		2,300,000	0
HHS/CDC	1,512,500	33,689,381		35,201,881	0
HHS/HRSA		4,000,000		4,000,000	0
PC		1,359,448		1,359,448	374,279
State		328,950		328,950	0
State/AF		150,000		150,000	0
USAID		35,785,442	15,500,000	51,285,442	0
<b>Total</b>	<b>1,512,500</b>	<b>77,613,221</b>	<b>15,500,000</b>	<b>94,625,721</b>	<b>374,279</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC	0	556,341	78,800	0			497,684	0	1,132,825
HBHC	11,283	165,854	2,198,114		151,571	0	4,050,452	0	6,577,274
HKID	11,283				17,724	150,000	4,862,949	0	5,041,956
HLAB	1,753	3,171	1,341,369				1,025,088	0	2,371,381
HMBL	0		1,009,628					0	1,009,628
HMIN	0								0
HTXD	0						6,754,489	0	6,754,489
HTXS	3,508	448,539	15,350,448	1,044,100			11,138,686	0	27,985,281
HVAB	0				0		0	0	0
HVCT	3,508	256,341	2,394,630				3,125,830	0	5,780,309
HVMS	250,088	59,512	2,052,159		866,330		1,713,382	0	4,941,471
HVOP	1,753	162,683			323,823		2,628,907	0	3,117,166
HVSI	5,086	222,195	1,126,079	424,600			196,697	0	1,974,657



HVTB	9,588	56,341	1,376,094	374,800			3,853,355	0	<b>5,670,178</b>
IDUP	0								<b>0</b>
MTCT	6,781	206,341	2,205,257	621,300			2,156,241	0	<b>5,195,920</b>
OHSS	3,975	106,341	3,079,890	1,535,200	0		3,298,608	0	<b>8,024,014</b>
PDCS	10,172		1,261,910				1,597,163	0	<b>2,869,245</b>
PDTX	10,172	56,341	1,727,503	0			4,385,911	0	<b>6,179,927</b>
	<b>328,950</b>	<b>2,300,000</b>	<b>35,201,881</b>	<b>4,000,000</b>	<b>1,359,448</b>	<b>150,000</b>	<b>51,285,442</b>	<b>0</b>	<b>94,625,721</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	5,589,720	0
HKID	4,925,134	0
HVTB	5,038,658	0
PDCS	1,920,227	0
<b>Total Technical Area Planned Funding:</b>	<b>17,473,739</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	2,317,297	0
HVSI	1,733,751	0
OHSS	7,919,390	0
<b>Total Technical Area Planned Funding:</b>	<b>11,970,438</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	1,028,800	0
HMBL	1,000,000	0
HVAB	0	0
HVCT	5,645,296	0
HVOP	3,010,552	0
MTCT	5,088,371	0
<b>Total Technical Area Planned Funding:</b>	<b>15,773,019</b>	<b>0</b>



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	6,695,287	0
HTXS	26,715,853	0
PDTX	4,736,441	0
<b>Total Technical Area Planned Funding:</b>	<b>38,147,581</b>	<b>0</b>

## Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	93 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	476,599	487,776
	Number of new ANC and L&D clients	515,208	516,916
	By: Known positives at entry	21,415	13,139
	By: Number of new positives identified	24,149	15,524
	Sum of Positives Status disaggregates	45,564	28,663
	Required only for DREAMS Countries - By Number of new positives: <15		188
	Required only for DREAMS Countries - By Number of new positives: 15-19		2,047
	Required only for DREAMS Countries - By Number of new positives: 20-24		3,267
	Required only for DREAMS Countries - By Number of new positives: 25+		7,781

	Required only for DREAMS Countries - By Number of known positives: <15		161
	Required only for DREAMS Countries - By Number of known positives: 15-19		860
	Required only for DREAMS Countries - By Number of known positives: 20-24		1,383
	Required only for DREAMS Countries - By Number of known positives: 25+		4,969
	Required only for DREAMS Countries - Denominator: <15		637
	Required only for DREAMS Countries - Denominator: <15-19		76,660
	Required only for DREAMS Countries - Denominator: 20-24		123,789
	Required only for DREAMS Countries - Denominator: 25+		164,620
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)		5,452

	Number of new ANC and L&D clients		5,738
	By: Known positives at entry		2,454
	By: Number of new positives identified		2,998
	Sum of Positives Status disaggregates		5,452
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		1
	Required only for DREAMS countries - By new positives: 15-19		102
	Required only for DREAMS countries - By new positives: 20-24		162
	Required only for DREAMS countries - By new positives: 25+		218
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator:		

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	90 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	41,101	39,634
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	45,564	42,651
	Life-long ART (including Option B+)	41,101	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	20,551	18,491
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	20,550	20,103

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	41,101	0
	Sum of New and Current disaggregates	41,101	38,594
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	n/a	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery		487
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)		514

	Life-long ART (including Option B+)		
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy		233
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy		245
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	0	0
	Sum of New and Current disaggregates		478
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		29,295
	Number of HIV-exposed infants registered in the birth		41,593

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		816
	HIV-infected: Not linked to ART		14
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		7,744
	HIV-uninfected: Still breastfeeding		5,346
	HIV-uninfected: Breastfeeding status unknown		2,736
	Other: In care but no test done		138
	Other: Lost to follow-up		9,893
	Other: Died		261
	Other: Transferred out		851
PMTCT_FO_TA	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		360
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		514
	HIV-infected: Linked to ART		10

	HIV-infected: Not linked to ART		0
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		36
	HIV-uninfected: Not breastfeeding		112
	HIV-uninfected: Still breastfeeding		75
	Other: Died		3
	Other: In care but no test done		1
	Other: Lost to follow-up		160
	Other: Transferred out		11
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	1,201	5,583
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by		



	maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by		

	maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	60,070	5,583
	By Age: <1	0	0
	By Age: 1-9	0	0
	By Age: 10-14	17,860	2,624
	By Age: 15-19	16,725	1,619
	By Age: 20-24	13,249	614
	By Age: 25-29		335
	By Age: 30-49		335
	By Age: 50+	2,023	56
	Sum of age disaggregates	60,070	4,913
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)		279
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)		5,304
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site		0
	By circumcision technique: Surgical VMMC		5,583
By circumcision technique:		0	

	Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery		4,187
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery		1,396
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	64 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	185,808	119,181
	Total number of people in the target population	290,325	2,071,282
	Age/sex: 10-14 Male	1,649	923
	Age/sex: 15-19 Male	21,525	5,526
	Age/sex: 20-24 Male	29,959	8,068
	Age/sex: 25-49 Male	38,814	13,104
	Age/sex: 50+ Male	6,625	155
	Age/sex: 10-14 Female	1,540	30,950
	Age/sex: 15-19 Female	14,814	25,347
	Age/sex: 20-24 Female	28,535	19,163

	Age/sex: 25-49 Female	35,666	15,760	
	Age/sex: 50+ Female	6,681	184	
	Sum of Age/Sex disaggregates	185,808	119,180	
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	64 %		
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,500	3,750	
	Total number of people in the target population	30,469	42,000	
	Age/sex: 10-14 Male	1,234	169	
	Age/sex: 15-19 Male	2,746	450	
	Age/sex: 20-24 Male	2,318	394	
	Age/sex: 25-49 Male	4,231	113	
	Age/sex: 50+ Male			
	Age/sex: 10-14 Female	1,050	394	
	Age/sex: 15-19 Female	2,343	1,050	
	Age/sex: 20-24 Female	1,970	919	
	Age/sex: 25-49 Female	3,608	261	
	Age/sex: 50+ Female			
	Sum of Age/Sex disaggregates	19,500	3,750	
	KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small	n/a	

	group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)		
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13,739	13,740
	Total estimated number of key population in the catchment area		44,130
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,776	7,776
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs	0	0

	(Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,963	5,964
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		24,300
	By key population type: Males who inject drugs (		

	Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,783,719	3,172,405
	By Test Result: Negative	1,599,849	2,920,603
	By Test Result: Positive	183,870	231,160
	Sum of Test Result disaggregates	1,783,719	3,151,763
	Test Result by Age and Sex:		395



	Positive: <1 Male		
	Test Result by Age and Sex: Positive: 1-4 Male		1,536
	Test Result by Age and Sex: Positive: 5-9 Male		4,063
	Test Result by Age and Sex: Positive: 10-14 Male		3,852
	Test Result by Age and Sex: Positive: 15-19 Male		3,627
	Test Result by Age and Sex: Positive: 20-24 Male		4,419
	Test Result by Age and Sex: Positive: 25-49 Male		57,137
	Test Result by Age and Sex: Positive: 50+ Male		10,979
	Test Result by Age and Sex: Positive: <1 Female		395
	Test Result by Age and Sex: Positive: 1-4 Female		1,580
	Test Result by Age and Sex: Positive: 5-9 Female		4,317
	Test Result by Age and Sex: Positive: 10-14 Female		4,158
	Test Result by Age and Sex: Positive: 15-19 Female		10,333
	Test Result by Age and Sex: Positive: 20-24 Female		23,219
	Test Result by Age and Sex: Positive: 25-49 Female		88,076
	Test Result by Age and Sex: Positive: 50+ Female		14,665
	Test Result by Age and Sex: Negative: <1 Male		16,112
	Test Result by Age and Sex:		64,426

	Negative: 1-4 Male		
	Test Result by Age and Sex: Negative: 5-9 Male		163,563
	Test Result by Age and Sex: Negative: 10-14 Male		149,884
	Test Result by Age and Sex: Negative: 15-19 Male		207,847
	Test Result by Age and Sex: Negative: 20-24 Male		177,682
	Test Result by Age and Sex: Negative: 25-49 Male		523,300
	Test Result by Age and Sex: Negative: 50+ Male		151,111
	Test Result by Age and Sex: Negative: <1 Female		15,566
	Test Result by Age and Sex: Negative: 1-4 Female		62,172
	Test Result by Age and Sex: Negative: 5-9 Female		163,297
	Test Result by Age and Sex: Negative: 10-14 Female		152,599
	Test Result by Age and Sex: Negative: 15-19 Female		212,727
	Test Result by Age and Sex: Negative: 20-24 Female		197,142
	Test Result by Age and Sex: Negative: 25-49 Female		515,252
	Test Result by Age and Sex: Negative: 50+ Female		166,977
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	134,230	398,800
	Aggregated Age/sex - USE WITH HQ PERMISSION	576,544	1,130,272

	ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	107,884	399,051
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	965,061	1,223,637
	Sum of Aggregated Age/Sex <15	242,114	797,851
	Sum of Aggregated Age/Sex 15+	1,541,605	2,353,909
	Sum of Aggregated Age/Sex disaggregates	1,783,719	3,151,760
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		29,388
	Service Delivery Point by Result: Antenatal Clinic - Negative		436,276
	Service Delivery Point by Result: Labor & delivery - All results		35,007
	Service Delivery Point by Result: Labor & delivery - Positive		2,688
	Service Delivery Point by Result: Labor & delivery - Negative		32,320
	Service Delivery Point by Result: Under 5 Clinic – All results		6
	Service Delivery Point by		0

	Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		1
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		0
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		0
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		0
	Service Delivery Point by Result: Tuberculosis – All results		16,419
	Service Delivery Point by Result: Tuberculosis - Positive		3,804
	Service Delivery Point by Result: Tuberculosis - Negative		12,609
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		106,899
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		6,857
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		100,035
	Service Delivery Point by Result: Outpatient Department – All Results		1,147,578

	Service Delivery Point by Result: Outpatient Department - Positive		88,939
	Service Delivery Point by Result: Outpatient Department - Negative		1,058,534
	Service Delivery Point by Result: Inpatient – All Results		79,848
	Service Delivery Point by Result: Inpatient - Positive		10,605
	Service Delivery Point by Result: Inpatient - Negative		69,242
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		624
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		289
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		335
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		3,119
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		127
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		2,992
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All		

	Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		44,639
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		617,109
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		1,980
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		24,013
	Service Delivery Point by Result: Mobile – All Results		121,159
	Service Delivery Point by Result: Mobile - Positive		29,664
	Service Delivery Point by Result: Mobile - Negative		91,495
	Service Delivery Point by Result: Home-based – All Results		0
	Service Delivery Point by Result: Home-based - Positive		0
	Service Delivery Point by Result: Home-based -		0

	Negative		
	Service Delivery Point by Result: Other – All Results		453,960
	Service Delivery Point by Result: Other - Positive		40,258
	Service Delivery Point by Result: Other - Negative		413,607
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	38,508
	By Test Result: Negative	0	
	By Test Result: Positive	0	
	Sum of Test Result disaggregates	0	
	Test Result by Age and Sex: Positive: <1 Male		6
	Test Result by Age and Sex: Positive: 1-4 Male		24
	Test Result by Age and Sex: Positive: 5-9 Male		62
	Test Result by Age and Sex: Positive: 10-14 Male		54
	Test Result by Age and Sex: Positive: 15-19 Male		45
	Test Result by Age and Sex: Positive: 20-24 Male		52
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		157
	Test Result by Age and Sex: Positive: <1 Female		7



	Test Result by Age and Sex: Positive: 1-4 Female		26
	Test Result by Age and Sex: Positive: 5-9 Female		66
	Test Result by Age and Sex: Positive: 10-14 Female		61
	Test Result by Age and Sex: Positive: 15-19 Female		59
	Test Result by Age and Sex: Positive: 20-24 Female		97
	Test Result by Age and Sex: Positive: 25-49 Female		1,186
	Test Result by Age and Sex: Positive: 50+ Female		215
	Test Result by Age and Sex: Negative: <1 Male		251
	Test Result by Age and Sex: Negative: 1-4 Male		1,006
	Test Result by Age and Sex: Negative: 5-9 Male		2,538
	Test Result by Age and Sex: Negative: 10-14 Male		2,297
	Test Result by Age and Sex: Negative: 15-19 Male		2,344
	Test Result by Age and Sex: Negative: 20-24 Male		1,934
	Test Result by Age and Sex: Negative: 25-49 Male		5,535
	Test Result by Age and Sex: Negative: 50+ Male		1,758
	Test Result by Age and Sex: Negative: <1 Female		243
	Test Result by Age and Sex: Negative: 1-4 Female		972

	Test Result by Age and Sex: Negative: 5-9 Female		2,534
	Test Result by Age and Sex: Negative: 10-14 Female		2,338
	Test Result by Age and Sex: Negative: 15-19 Female		2,343
	Test Result by Age and Sex: Negative: 20-24 Female		1,956
	Test Result by Age and Sex: Negative: 25-49 Female		5,683
	Test Result by Age and Sex: Negative: 50+ Female		1,936
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	
	Sum of Aggregated Age/Sex <15	0	
	Sum of Aggregated Age/Sex 15+	0	
	Sum of Aggregated Age/Sex disaggregates	0	
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by		346

	Result: Antenatal Clinic - Positive		
	Service Delivery Point by Result: Antenatal Clinic - Negative		4,888
	Service Delivery Point by Result: Labor & delivery - All results		601
	Service Delivery Point by Result: Labor & delivery - Positive		41
	Service Delivery Point by Result: Labor & delivery - Negative		560
	Service Delivery Point by Result: Under 5 Clinic – All results		
	Service Delivery Point by Result: Under 5 Clinic - Positive		
	Service Delivery Point by Result: Under 5 Clinic - Negative		
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		
	Service Delivery Point by Result: Tuberculosis – All results		648

	Service Delivery Point by Result: Tuberculosis - Positive		152
	Service Delivery Point by Result: Tuberculosis - Negative		496
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		1,935
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		105
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		1,829
	Service Delivery Point by Result: Outpatient Department – All Results		7,010
	Service Delivery Point by Result: Outpatient Department - Positive		507
	Service Delivery Point by Result: Outpatient Department - Negative		6,503
	Service Delivery Point by Result: Inpatient – All Results		3,244
	Service Delivery Point by Result: Inpatient - Positive		454
	Service Delivery Point by Result: Inpatient - Negative		2,790
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		
	Service Delivery Point by		

	Result: HIV care and treatment clinic - Positive		
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		848
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		10,683
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		
	Service Delivery Point by		

	Result: Voluntary Counseling & Testing (standalone) - Negative		
	Service Delivery Point by Result: Mobile – All Results		
	Service Delivery Point by Result: Mobile - Positive		
	Service Delivery Point by Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		
	Service Delivery Point by Result: Home-based - Positive		
	Service Delivery Point by Result: Home-based - Negative		
	Service Delivery Point by Result: Other – All Results		7,136
	Service Delivery Point by Result: Other - Positive		603
	Service Delivery Point by Result: Other - Negative		6,533
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		
	Test Result by Aggregated Age and Sex: Negative <15 Female		
	Test Result by Aggregated Age and Sex: Negative 15+		

	Female		
	Test Result by Aggregated Age and Sex: Positive <15 Male		
	Test Result by Aggregated Age and Sex: Positive 15+ Male		
	Test Result by Aggregated Age and Sex: Positive <15 Female		
	Test Result by Aggregated Age and Sex: Positive 15+ Female		
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		21,289
	Total number of registered new and relapsed TB cases, during the reporting period.		22,656
	Sex: Male		8,691
	Sex: Female		12,597
	Age: <1		66
	Age: 1-4		364
	Age: 5-9		719
	Age: 10-14		629
	Age 15-19		
	Age: 20+		18,991
	Status: Positive		12,296

	Status: Negative		8,992
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		1,462
	Total number of registered new and relapsed TB cases, during the reporting period.		1,556
	Age 15-19		
	Age: <1		3
	Age: 1-4		14
	Age: 10-14		25
	Age: 20+		1,357
	Age: 5-9		28
	Sex: Female		940
	Sex: Male		523
	Status: Negative		634
	Status: Positive		828
	GEND_GBV_DSD	Number of people receiving post-GBV care	
Age/Sex: <10 Male			0
Age/Sex: 10-14 Male			0
Age/Sex: 15-17 Male			202
Age/Sex: 18-24 Male			604
Age/Sex: 25+ Male			537
Age/Sex: <10 Female			0
Age/Sex: 10-14 Female			527
Age/Sex: 15-17 Female		437	

	Age/Sex: 18-24 Female		2,013
	Age/Sex: 25+ Female		805
	Sum of Age/Sex Disaggregates		5,125
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)		2,597
	By type of service: Sexual Violence (Post-Rape Care)		2,528
	By PEP service provision (related to sexual violence services provided)		
	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	257,489
	Age/Sex: <10 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-19 Male		1,389
	Age/Sex: 20-24 Male		20,379
	Age/Sex: 25+ Male		96,350
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 15-19 Female		964
	Age/Sex: 20-24 Female		21,668
	Age/Sex: 25+ Female		116,739
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25+		
	Sum of Age disaggregates		
GEND_NORM_DSD			
GEND_NORM_TA	Number of people		1,750

	completing an intervention pertaining to gender norms, that meets minimum criteria		
	Age/Sex: <10 Male		
	Age/Sex: 10-14 Male		204
	Age/Sex: 15-19 Male		213
	Age/Sex: 20-24 Male		139
	Age/Sex: 25+ Male		64
	Age/Sex: <10 Female		
	Age/Sex: 10-14 Female		378
	Age/Sex: 15-19 Female		487
	Age/Sex: 20-24 Female		184
	Age/Sex: 25+ Female		81
	By Age: 0-9		
	By Age: 10-14		
	By Age: 15-19		
	By Age: 20-24		
	By Age: 25+		
	Sum of Age disaggregates		
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		0
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		0
	Age/Sex: 5-9 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-17 Male		0
	Age/Sex: 18-24 Male		0
	Age/Sex: 25+ Male		0
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		0

	Age/Sex: 5-9 Female		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 15-17 Female		0
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		0
	Age/Sex: 25+ Female		0
	Sum of Age/Sex disaggregates		0
OVC_ACC_TA	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services		
	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-9 Male		
	Age/Sex: 10-14 Male		
	Age/Sex: 15-17 Male		
	Age/Sex: 18-24 Male		
	Age/Sex: 25+ Male		0
	Age/Sex: <1 Female		
	Age/Sex: 1-4 Female		
	Age/Sex: 5-9 Female		
	Age/Sex: 10-14 Female		
	Age/Sex: 15-17 Female		
	Age/Sex: 18-24 Female		
	Age/Sex: 25+ Female		
	Sum of Age/Sex disaggregates		0
	OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected	310,400

	by HIV/AIDS		
	Age/Sex: <1 Male		8,827
	Age/Sex: 1-4 Male		21,092
	Age/Sex: 5-9 Male		19,498
	Age/Sex: 10-14 Male		16,113
	Age/Sex: 15-17 Male		9,126
	By: Age/sex: Male 18-24		145
	By: Age/sex: Male 25+		0
	Age/Sex: <1 Female		8,831
	Age/Sex: 1-4 Female		20,567
	Age/Sex: 5-9 Female		19,544
	Age/Sex: 10-14 Female		28,401
	Age/Sex: 15-17 Female		15,565
	By: Age/sex: 18-24 Female		29,575
	By: Age/sex: 25+ Female		10,108
	Sum of Age/Sex disaggregates		167,564
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS		



	countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		



	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age		

	and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS		

	countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-4		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		7,817
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		7,911
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		6,204
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		10,294



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		7,798
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		6,353
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		3,575
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		0
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for	700	6,181

	children and families affected by HIV/AIDS		
	Age/Sex: <1 Male		133
	Age/Sex: 1-4 Male		298
	Age/Sex: 5-9 Male		536
	Age/Sex: 10-14 Male		447
	Age/Sex: 15-17 Male		356
	By age/sex: 18-24 Male		415
	By age/sex: 25+ Male		503
	Age/Sex: <1 Female		152
	Age/Sex: 1-4 Female		340
	Age/Sex: 5-9 Female		622
	Age/Sex: 10-14 Female		830
	Age/Sex: 15-17 Female		407
	By age/sex: 18-24 Female		502
	By age/sex: 25+ Female		640
	Sum of Age/Sex disaggregates		3,585
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4		0
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9		600
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14		

	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24		400
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Education		

	Support Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24		



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24		
	Required only for DREAMS		



	countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Social		

	Protection Male <1		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4		466
	Required only for DREAMS countries: By Service Area,		365



	age and sex: Economic Strengthening Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24		403
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1		133
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4		298
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9		322
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14		294
	Required only for DREAMS		278

	countries: By Service Area, age and sex: Economic Strengthening Male 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24		267
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+		499
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17		
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24		

	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+		
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	463,312	690,264
	Age/sex: <1 Male		12,256
	Age/sex: 1-4 Male		4,902
	Age/sex: 5-9 Male		9,825
	Age/sex: 10-14 Male		8,258
	Age/sex: 15-19 Male		5,454
	Age/sex: 20-24 Male		6,125
	Age/sex: 25-49 Male		164,422
	Age/sex: 50+ Male		47,146
	Age/sex: <1 Female		1,103
	Age/sex: 1-4 Female		4,832
	Age/sex: 5-9 Female		9,295
	Age/sex: 10-14 Female		8,395
	Age/sex: 15-19 Female		11,470
	Age/sex: 20-24 Female		34,358
	Age/sex: 25-49 Female		316,694
	Age/sex: 50+ Female		45,292
	Sun of Age/Sex disaggregates		689,827
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	23,165	
	Aggregated Age/sex - USE WITH HQ PERMISSION	157,525	

	ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	23,165	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	259,457	
	Sum of Aggregated Age/Sex disaggregates	463,312	
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		17,841
	Age/sex: <1 Male		1,249
	Age/sex: 1-4 Male		128
	Age/sex: 5-9 Male		257
	Age/sex: 10-14 Male		216
	Age/sex: 15-19 Male		134
	Age/sex: 20-24 Male		125
	Age/sex: 25-49 Male		4,156
	Age/sex: 50+ Male		1,211
	Age/sex: <1 Female		30
	Age/sex: 1-4 Female		125
	Age/sex: 5-9 Female		242
	Age/sex: 10-14 Female		219
	Age/sex: 15-19 Female		272
	Age/sex: 20-24 Female		847
	Age/sex: 25-49 Female		7,477
	Age/sex: 50+ Female		1,153
	Sum of Age/Sex		17,841

	disaggregates		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female		
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	282,379	188,665
	Age/sex: <1 Male		2,901
	Age/sex: 1-4 Male		1,332
	Age/sex: 5-9 Male		2,665
	Age/sex: 10-14 Male		2,239
	Age/sex: 15-19 Male		1,583
	Age/sex: 20-24 Male		1,646
	Age/sex: 25-49 Male		45,530
	Age/sex: 50+ Male		13,035
	Age/sex: <1 Female		255
	Age/sex: 1-4 Female		1,322

	Age/sex: 5-9 Female		2,523
	Age/sex: 10-14 Female		2,276
	Age/sex: 15-19 Female		3,085
	Age/sex: 20-24 Female		9,313
	Age/sex: 25-49 Female		86,585
	Age/sex: 50+ Female		12,270
	Sum of Age/sex disaggregates		188,560
	Aggregated Age/sex: <15 Male	14,119	
	Aggregated Age/sex: 15+ Male	96,010	
	Aggregated Age/sex: <15 Female	14,121	
	Aggregated Age/sex: 15+ Female	158,129	
	Sum of Aggregated Age/sex disaggregates	282,379	
CARE_NEW_TA	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		2,728
	Age/sex: <1 Female		4
	Age/sex: 1-4 Female		20
	Age/sex: 5-9 Female		36
	Age/sex: 10-14 Female		34
	Age/sex: 15-19 Female		42
	Age/sex: 20-24 Female		129
	Age/sex: 25-49 Female		1,141

	Age/sex: 50+ Female		180
	Age/sex: <1 Male		191
	Age/sex: 1-4 Male		20
	Age/sex: 5-9 Male		39
	Age/sex: 10-14 Male		34
	Age/sex: 15-19 Male		21
	Age/sex: 20-24 Male		19
	Age/sex: 25-49 Male		637
	Age/sex: 50+ Male		181
	Aggregated Age/sex: <15 Female		
	Aggregated Age/sex: <15 Male		
	Aggregated Age/sex: 15+ Female		
	Aggregated Age/sex: 15+ Male		
	Sum of Aggregated Age/sex disaggregates	282,379	
	Sum of age/sex disaggregates		2,728
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		5,948
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period		

	and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		1
	Age: 1-4		43
	Age: 5-9		119
	Age: 10-14		152
	Age: 15-19		94
	Age: 20+		5,522
	Sum of Age disaggregates		5,931
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		
	Sex: Male		2,744
	Sex: Female		3,192
TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		87
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment:		

	clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		1
	Age: 10-14		2
	Age: 15-19		3
	Age: 20+		81
	Sum of Age disaggregates		87
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		
	Sex: Male		32
	Sex: Female		55
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		115,633
	Number of HIV positive adults and children who received care and treatment services		117,986
	Age: <1		391
	Age: 1-4		1,674
	Age: 5-14		5,947

	Age: 15-17		1,446
	Age: 18+ years		106,175
	Sum of Age disaggregates		115,633
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		
	By Pregnancy/Postpartum Status: Pregnant		23,940
	By Pregnancy/Postpartum Status: Postpartum		6,509
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	95 %	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	9,147	10,493
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	9,628	11,287
	Age: <1		24
	Age: 1-4		182
	Age: 5-9		345
	Age: 10-14		304
	Age: 15-19		229

	Age: 20+		9,409
	Sum of Age disaggregates		10,493
	Male		4,428
	Female		6,063
	Sum of Sex disaggregates		10,491
	Newly tested		
	Known HIV-positive		7,978
	Sum of Test Status disaggregates		7,978
	Aggregated Age: <15		0
	Aggregated Age: 15+		0
	Sum of Aggregated Age disaggregates		0
	Timeliness: Art initiation <8 weeks of start of TB treatment		5,420
	Timeliness: Art initiation >8 weeks of start of TB treatment		284
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		720
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the		777

	reporting period		
	Age: <1		1
	Age: 1-4		7
	Age: 5-9		14
	Age: 10-14		12
	Age: 15-19		17
	Age: 20+		669
	Sum of Age disaggregates		720
	Aggregated Age: <15		
	Aggregated Age: 15+		
	Sum of Aggregated Age disaggregates		
	Male		257
	Female		463
	Sum of Sex disaggregates		720
	Known HIV-positive		550
	Newly tested		
	Sum of Test Status disaggregates		550
	Timeliness: Art initiation <8 weeks of start of TB treatment		243
	Timeliness: Art initiation >8 weeks of start of TB treatment		90
TB_OUTCOME_DSD	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases		10,456

	who are HIV-positive in the treatment cohort		
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		11,279
	Outcome by Age: Cured <1		18
	Outcome by Age: Cured 1-4		145
	Outcome by Age: Cured 5-9		298
	Outcome by Age: Cured 10-14		270
	Outcome by Age: Cured: 15-19		197
	Outcome by Age: Cured 20+		8,284
	Outcome by Age: Treatment Complete <1		0
	Outcome by Age: Treatment Complete 1-4		1
	Outcome by Age: Treatment Complete 5-9		2
	Outcome by Age: Treatment Complete 10-14		4
	Outcome by Age: Treatment Complete 15-19		2
	Outcome by Age: Treatment Complete 20+		161
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment		0



	Failed 10-14		
	Outcome by Age: Treatment Failed 15-19		0
	Outcome by Age: Treatment Failed 20+		102
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		2
	Outcome by Age: Died 5-9		11
	Outcome by Age: Died 10-14		9
	Outcome by Age: Died 15-19		8
	Outcome by Age: Died 20+		646
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		0
	Outcome by Age: Lost to Follow-up 5-9		2
	Outcome by Age: Lost to Follow-up 10-14		2
	Outcome by Age: Lost to Follow-up 15-19		2
	Outcome by Age: Lost to Follow-up 20+		157
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		0
	Outcome by Age: Not		110

	Evaluated 20+		
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		58
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_OUTCOME_TA	TB_OUTCOME_TA TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		723

	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		777
	Outcome by Age: Cured <1		0
	Outcome by Age: Cured 1-4		6
	Outcome by Age: Cured 5-9		12
	Outcome by Age: Cured 10-14		11
	Outcome by Age: Cured 15-19		15
	Outcome by Age: Cured 20+		590
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Age: Treatment Complete <1		0
	Outcome by Age: Treatment Complete 1-4		0
	Outcome by Age: Treatment Complete 5-9		0
	Outcome by Age: Treatment Complete 10-14		0
	Outcome by Age: Treatment Complete 15-19		0
	Outcome by Age: Treatment Complete 20+		11
	Outcome by Sex: Treatment Complete Female		8
	Outcome by Sex: Treatment Complete Male		4
	Outcome by Age: Treatment		0



	Failed <1		
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment Failed 10-14		0
	Outcome by Age: Treatment Failed 15-19		0
	Outcome by Age: Treatment Failed 20+		7
	Outcome by Sex: Treatment Failed Female		
	Outcome by Sex: Treatment Failed Male		
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0
	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0
	Outcome by Age: Died 15-19		0
	Outcome by Age: Died 20+		42
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		0
	Outcome by Age: Lost to Follow-up 5-9		0
	Outcome by Age: Lost to Follow-up 10-14		0
	Outcome by Age: Lost to Follow-up 15-19		0

	Outcome by Age: Lost to Follow-up 20+		12
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		0
	Outcome by Age: Not Evaluated 20+		8
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	99 %	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	458,679	668,959
	Number of HIV positive adults and children who	463,312	690,264

	received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		2,058
	Age: 1-4		9,562
	Age: 5-9		18,649
	Age: 10-14		16,067
	Age: 15-19		15,199
	Age: 20+		604,378
	Sum of Age disaggregates		665,913
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Male		306,890
	Sex: Female		359,478
	Sum of Sex disaggregates		666,368
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period		17,484

	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load		17,841
	Age: <1		51
	Age: 1-4		250
	Age: 5-9		489
	Age: 10-14		421
	Age: 15-19		398
	Age: 20+		15,875
	Sum of Age disaggregates		17,484
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		
	Sum of Aggregated Age disaggregates		
	Sex: Female		11,220
	Sex: Male		6,264
	Sum of Sex disaggregates		17,484
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	50 %	
	Number of infants who had a virologic HIV test within 12 months of birth during the	22,211	33,339

	reporting period		
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	44,421	
	By infants who received a virologic test within 2 months of birth		12,330
	By infants who received their first virologic HIV test between 2 and 12 months of age		20,871
	Sum of Infant Age disaggregates		33,201
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		333
	Number of infants with a positive virological test result within 12 months of birth		595
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period		410
	Number of HIV- positive pregnant women identified		

	during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		151
	By infants who received their first virologic HIV test between 2 and 12 months of age		258
	Sum of Infant Age disaggregates		409
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		4
	Number of infants with a positive virological test result within 12 months of birth		6
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		39,715
	Number of HIV-positive		

	pregnant women identified in the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		487
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		164,010
	Age/Sex: <1 Male		3,663
	Age/Sex: 1-4 Male		4,038
	Age/Sex: 5-9 Male		3,590
	Age/Sex: 10-14 Male		2,205
	Age/Sex: 15-19 Male		4,268
	Age/Sex: 20-24 Male		8,237
	Age/Sex: 25-49 Male		32,627
	Age/Sex: 50+ Male		5,847
	Age/Sex: <1 Female		3,650
	Age/Sex: 1-4 Female		4,063

	Age/Sex: 5-9 Female		3,627
	Age/Sex: 10-14 Female		5,456
	Age/Sex: 15-19 Female		7,454
	Age/Sex: 20-24 Female		13,720
	Age/Sex: 25-49 Female		54,268
	Age/Sex: 50+ Female		7,297
	Number of HIV-infected adults and children receiving care and support services outside of the health facility		6,201
	Age/Sex: <1 Female		152
	Age/Sex: <1 Male		133
	Age/Sex: 1-4 Female		340
	Age/Sex: 1-4 Male		298
	Age/Sex: 10-14 Female		795
	Age/Sex: 10-14 Male		421
	Age/Sex: 15-19 Female		388
	Age/Sex: 15-19 Male		351
	Age/Sex: 20-24 Female		569
	Age/Sex: 20-24 Male		455
	Age/Sex: 25-49 Female		659
	Age/Sex: 25-49 Male		520
	Age/Sex: 5-9 Female		600
	Age/Sex: 5-9 Male		520
	Age/Sex: 50+ Female		
	Age/Sex: 50+ Male		
CARE_COMM_TA			
	Number of adults and children receiving antiretroviral therapy (ART)	469,189	655,112
	Age/Sex: <1 Male		524
	Age/Sex: 1-4 Male		4,649
	Age/Sex: 5-14 Male		23,687
TX_CURR_DSD			

	Age/Sex: 15-19 Male		6,340
	Age/Sex: 20+ Male		202,914
	Age/Sex: <1 Female		628
	Age/Sex: 1-4 Female		5,025
	Age/Sex: 5-14 Female		23,502
	Age/Sex: 15-19 Female		8,885
	Age/Sex: 20+ Female		378,808
	Aggregated Age/Sex: <1 Male	1,172	
	Aggregated Age/Sex: <1 Female	1,172	
	Aggregated Age/Sex: 15+ Male	147,807	
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female	274,502	
	Sum of Aggregated Age/Sex <15	46,880	
	Sum of Aggregated Age/Sex 15+	422,309	
	Sum of Aggregated Age/Sex disaggregates	469,189	
	Aggregated Age/Sex: 1-14 Male		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	2,344	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)		17,166
	Age/Sex: <1 Male		11
	Age/Sex: 1-4 Male		101
	Age/Sex: 5-14 Male		515

	Age/Sex: 15-19 Male		142
	Age/Sex: 20+ Male		5,391
	Age/Sex: <1 Female		13
	Age/Sex: 1-4 Female		109
	Age/Sex: 5-14 Female		511
	Age/Sex: 15-19 Female		220
	Age/Sex: 20+ Female		10,153
	Sum of Age/Sex disaggregations		17,166
	Aggregated Age/Sex: <1 Male		
	Aggregated Age/Sex: <1 Female		
	Aggregated Age/Sex: 1-14 Male		
	Aggregated Age/Sex: 15+ Male		
	Aggregated Age/Sex: 1-14 Female		
	Aggregated Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex <15		
	Sum of Aggregated Age/Sex 15+		
	Sum of Aggregated Age/Sex disaggregates		
	Sum of Aggregated Age/Sex (<1 and 1-14) <15		
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	128,790	174,849
	By Age/Sex: <1 Male	725	1,303
	By Age/Sex: 1-4 Male	4,340	3,071

	By Age/Sex: 5-9 Male	1,449	2,484
	By Age/Sex: 10-14 Male	725	1,885
	By Age/Sex: 15-19 Male	10,044	1,422
	By Age/Sex: 20-24 Male	10,044	2,384
	By Age/Sex: 25-49 Male	18,069	44,082
	By Age/Sex: 50+ Male	2,820	7,352
	By Age/Sex: <1 Female	725	1,403
	By Age/Sex: 1-4 Female	4,340	2,751
	By Age/Sex: 5-9 Female	1,449	2,131
	By Age/Sex: 10-14 Female	2,455	2,197
	By Age/Sex: 15-19 Female	18,542	4,513
	By Age/Sex: 20-24 Female	18,542	16,277
	By Age/Sex: 25-49 Female	33,362	75,365
	By Age/Sex: 50+ Female	2,895	6,099
	Sum of Age/Sex disaggregates	130,526	174,719
	Aggregated Grouping by Age: <1 Male	725	
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male	40,977	
	Aggregated Grouping by Age/Sex: <1 Female	725	
	Aggregated Grouping by Age/Sex: 15+ Female	73,341	
	Sum of Aggregated Age/Sex disaggregates	128,790	
	Pregnancy status	27,012	35,594
	Breastfeeding status	5,692	9,780
	Aggregated Grouping by Age/Sex: 1-14 Female		
TX_NEW_TA	Number of adults and		2,553

	children newly enrolled on antiretroviral therapy (ART)		
	By Age/Sex: <1 Male		21
	By Age/Sex: 1-4 Male		50
	By Age/Sex: 5-9 Male		41
	By Age/Sex: 10-14 Male		28
	By Age/Sex: 15-19 Male		18
	By Age/Sex: 20-24 Male		29
	By Age/Sex: 25-49 Male		642
	By Age/Sex: 50+ Male		108
	By Age/Sex: <1 Female		22
	By Age/Sex: 1-4 Female		39
	By Age/Sex: 5-9 Female		33
	By Age/Sex: 10-14 Female		34
	By Age/Sex: 15-19 Female		61
	By Age/Sex: 20-24 Female		235
	By Age/Sex: 25-49 Female		1,097
	By Age/Sex: 50+ Female		90
	Sum of Age/Sex disaggregates		2,548
	Aggregated Grouping by Age: <1 Male		
	Aggregated Grouping by Age/Sex: 1-14 Male		
	Aggregated Grouping by Age/Sex: 15+ Male		
	Aggregated Grouping by Age: <1 Female		
	Aggregated Grouping by Age/Sex: 1-14 Female		
	Aggregated Grouping by Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex		

	disaggregates		
	Pregnancy status		556
	Breastfeeding status		152
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	82 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	100,177	138,872
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	122,165	173,768
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,822
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		2,842
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are		966

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		47,354
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,930
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		2,829
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,647
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		79,165
	Age/Sex: <5 Male (Denominator: Total number of adults and children who		3,687

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		3,076
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,290
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		57,982

	to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		3,708
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		3,149
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		4,521
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		94,890

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		10,098
	Numerator by Status: Breastfeeding		25,319
	Denominator by Status: Pregnant		11,447
	Denominator by Status: Breastfeeding		33,098
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		2,043
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		2,553
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		27

	ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		42
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		14
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		636
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		28
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		42
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating		25

	ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		1,229
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		54
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		35
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost		13

	to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		778
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		55
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		48
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning		69

	of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		1,489
	Numerator by Status: Pregnant		141
	Numerator by Status: Breastfeeding		389
	Denominator by Status: Pregnant		178
	Denominator by Status: Breastfeeding		487
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		266,626
	Number of adults and children on ART at least 6 months whose medical		569,101

	records were reviewed		
	Age/Sex: <1 Male		108
	Age/Sex: 1-4 Male		1,359
	Age/Sex: 5-14 Male		6,902
	Age/Sex: 15-19 Male		2,445
	Age/Sex: 20+ Male		84,710
	Age/Sex: <1 Female		141
	Age/Sex: 1-4 Female		1,464
	Age/Sex: 5-14 Female		6,848
	Age/Sex: 15-19 Female		3,539
	Age/Sex: 20+ Female		158,636
	Results Category: Undetectable		222,968
	Results Category: Detectable		42,396
TX_VIRAL_TA	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months.		7,563
	Number of adults and children on ART at least 6 months whose medical records were reviewed.		15,892
	Age/Sex: <1 Male		4
	Age/Sex: 1-4 Male		40
	Age/Sex: 5-14 Male		196
	Age/Sex: 15-19 Male		64
	Age/Sex: 20+Male		2,401
	Age/Sex: <1 Female		6

	Age/Ses: 1-4 Female		42
	Age/Sex: 5-14 Female		195
	Age/Sex: 15-19 Female		97
	Age/Sex: 20+ Female		4,518
	Result Category: Undetectable		6,361
	Result Category: Detectable		1,201
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	21	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	223	
	By clinical laboratories		
	By Point-of-care testing sites		
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		238,953
	Number of viral load tests		264,958

	performed from adults and children on ART within the current reporting period		
	Age/Sex: <1 Male		93
	Age/Sex: 1-4 Male		1,226
	Age/Sex: 5-14 Male		6,214
	Age/Sex: 15-19 Male		2,054
	Age/Sex: 20+ Male		75,895
	Age/Sex: <1 Female		132
	Age/Sex: 1-4 Female		1,312
	Age/Sex: 5-14 Female		6,160
	Age/Sex: 15-19 Female		3,095
	Age/Sex: 20+ Female		142,518
	Pregnant		15,598
	Breastfeeding		42,988
	Test indication: Routine monitoring		214,881
	Test indication: Targeted monitoring		
TX_UNDETECT_TA	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		6,806
	Number of viral load tests performed from adults and children on ART within the current reporting period		7,562
	Age/Sex: <1 Female		5

	Age/Sex: <1 Male		2
	Age/Sex: 1-4 Female		37
	Age/Sex: 1-4 Male		36
	Age/Sex: 15-19 Female		87
	Age/Sex: 15-19 Male		57
	Age/Sex: 20+ Female		4,068
	Age/Sex: 20+ Male		2,161
	Age/Sex: 5-14 Female		176
	Age/Sex: 5-14 Male		177
	Breastfeeding		1,303
	Pregnant		471
	Test indication: Routine monitoring		6,123
	Test indication: Targeted monitoring		683
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	224	
	By Graduates: Doctors		
	By Graduates: Nurses		
	By Graduates: Midwives		
	By Graduates: Social service workers		
	By Graduates: Laboratory professionals		
	By Graduates: Other		
	Sum of Graduates disaggregated		

FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	98 %	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	347	85
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	355	99
	Service delivery type: Care and Support		0
	Service delivery type: Treatment		2
	Service delivery type: PMTCT		80
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		

## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9266	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	1,163,500
9276	National AIDS Commission, Malawi	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1
9281	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	4,000,000
9883	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
10427	Malawi Blood Transfusion Service	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,000,000
11453	U.S. Peace Corps	Other USG	U.S. Peace Corps	GHP-State	407,454

		Agency			
12105	Dignitas International	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	6,421,350
12107	Partners in Hope	FBO	U.S. Agency for International Development	GHP-State, GHP-USAID	4,415,490
12109	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	0
12111	Ministry of Health, Malawi	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,239,000
12116	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
12118	Banja La Mtsogolo	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	0
12119	Global AIDS Interfaith Alliance	FBO	U.S. Agency for International Development	GHP-State	0
12126	Feed the Children	NGO	U.S. Agency for International Development	GHP-State	0
12130	Baylor College of Medicine Children's Foundation	University	U.S. Agency for International Development	GHP-State, GHP-USAID	6,013,481
12131	Christian Health Association of	FBO	U.S. Department of Health and	GHP-State	1,200,000



# PEPFAR

U.S. President's Emergency Plan for AIDS Relief

	Malawi		Human Services/Centers for Disease Control and Prevention		
12638	JHPIEGO	University	U.S. Agency for International Development	GHP-State, GHP-USAID	5,098,850
13101	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	500,000
14113	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,457,803
14246	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	885,000
14432	JHPIEGO	University	U.S. Department of Defense	GHP-State	0
14441	Lighthouse	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,917,316
14442	BAOBAB Health Partnership	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	2,900,000

			Prevention		
14443	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14448	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	6,695,287
15888	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	800,000
16485	Tovwirane HIV/AIDS Organization	NGO	U.S. Agency for International Development	GHP-State	0
16486	Save The Children Federation Inc	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	500,000
16678	Management Sciences for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,752,376
16704	TBD	TBD	Redacted	Redacted	Redacted
16716	Counterpart International	NGO	U.S. Agency for International Development	GHP-USAID	1,200,000
16794	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
17097	Project Concern	NGO	U.S. Department	GHP-State	1,520,000

	International		of Defense		
17268	Columbia University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
17341	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,800,000
17451	Universtiy of Washington	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,975,385
17480	TBD	TBD	Redacted	Redacted	Redacted
17487	National Registration Bureau Malawi	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
17488	University of Malawi College of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	760,000

			Prevention		
17585	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,210,000
17590	Population Council	NGO	U.S. Agency for International Development	GHP-State	372,248
17594	Population Services International	NGO	U.S. Agency for International Development	GHP-State	600,000
17720	VISTA PARTNERS	Implementing Agency	U.S. Department of Defense	GHP-State	150,000
18005	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	2,853,023
18024	TBD	TBD	Redacted	Redacted	Redacted
18025	TBD	TBD	Redacted	Redacted	Redacted
18028	World Learning	NGO	U.S. Agency for International Development	GHP-State	500,000
18045	JHPIEGO	University	U.S. Department of Defense	GHP-State	450,000
18063	TBD	TBD	Redacted	Redacted	Redacted
18125	TBD	TBD	Redacted	Redacted	Redacted
18142	Marie Stopes International	NGO	U.S. Agency for International Development	GHP-State	0



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 9266</b>	<b>Mechanism Name: DELIVER</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,163,500</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	663,500
GHP-USAID	500,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>9266</b>
----------------------	-------------



<b>Mechanism Name:</b>	<b>DELIVER</b>		
<b>Prime Partner Name:</b>	<b>John Snow, Inc.</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	195,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	747,500	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	221,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9276</b>	<b>Mechanism Name: National AIDS Commission, Malawi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National AIDS Commission, Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 9276			
<b>Mechanism Name:</b> National AIDS Commission, Malawi			
<b>Prime Partner Name:</b> National AIDS Commission, Malawi			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016	Planning Budget Targets
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	32,690		Redacted

HTC_TST_DSD	By Test Result: Negative	29,421		Redacted
HTC_TST_DSD	By Test Result: Positive	3,269		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	32,690		Redacted
HTC_TST_DSD	Age/sex: <1 Male	48		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	193		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	193		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	169		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	2,676		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	2,676		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	4,817		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	787		Redacted
HTC_TST_DSD	Age/sex: <1 Female	48		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	193		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	193		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	169		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,195		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	5,195		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	9,351		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	787		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	32,690		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	603		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,956		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	603		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,528		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,206		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	31,484		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	32,690		Redacted

HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,059		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	0		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	0		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	0		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	303		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,060		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	303		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,393		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	6,059		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	4,316		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	216		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,467		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	216		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2,417		Redacted

CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	4,316		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	4,316		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,356		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	3		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	27		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	30		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	1,483		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	3		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	27		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	30		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	2,754		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	120		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	3		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	3		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	60		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,483		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	60		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,754		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	120		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,237		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,357		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	6		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	566		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	3		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	20		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	7		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	3		Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Male	44		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	44		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	80		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	12		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	3		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	20		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	7		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	3		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	81		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	81		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	146		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	12		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	566		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	3		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	33		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	180		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	3		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	33		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	320		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	566		Redacted
TX_NEW_DSD	Pregnancy status	119		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	464		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	566		Redacted



	period, including those who have died, those who have stopped ART, and those lost to follow-up			
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	5,998		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	6,059		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 9281</b>	<b>Mechanism Name: I-TECH</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,535,200
----------------------------	-----------

## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 9281			
<b>Mechanism Name:</b> I-TECH			
<b>Prime Partner Name:</b> University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	374,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	424,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,535,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	621,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,044,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	270		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,500		Redacted
VMMC_CIRC_DS D	By Age: <1	0		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	4,014		Redacted
VMMC_CIRC_DS D	By Age: 15-19	3,759		Redacted
VMMC_CIRC_DS D	By Age: 20-24	2,978		Redacted
VMMC_CIRC_DS D	By Age: 25-49	2,295		Redacted
VMMC_CIRC_DS D	By Age: 50+	454		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	13,500		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	280		Redacted
VMMC_CIRC_DS	By HIV status: Number of HIV-negative	14,400		Redacted

D	clients (tested HIV negative at VMMC program)			
VMMC_CIRC_DS D	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	20		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	14,700		Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	13,010		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	1,690		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,075		Redacted
HTC_TST_DSD	By Test Result: Negative	24,367		Redacted
HTC_TST_DSD	By Test Result: Positive	2,708		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	27,075		Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	0		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	0		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	8,123		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	7,581		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	5,957		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	4,603		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	811		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	27,075		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,123		Redacted



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,952		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,123		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	18,952		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	27,075		Redacted
HTC_TST_TA	By Test Result: Negative	6,450		Redacted
HTC_TST_TA	By Test Result: Positive	100		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	6,550		Redacted
HTC_TST_TA	Age/sex: <1 Male	0		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	0		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	0		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	100		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,310		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	3,080		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	1,965		Redacted
HTC_TST_TA	Age/sex: 50+ Male	95		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	6,550		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	330		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,220		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	330		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	6,220		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	6,550		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 9883</b>	<b>Mechanism Name: Prevention for Populations and Settings with High Risk Behaviors</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	9883		
<b>Mechanism Name:</b>	Prevention for Populations and Settings with High Risk Behaviors		
<b>Prime Partner Name:</b>	Population Services International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2015	2016
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	100	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,000	
VMMC_CIRC_DSD	By Age: 10-14	1,486	
VMMC_CIRC_DSD	By Age: 15-19	1,392	
VMMC_CIRC_DSD	By Age: 20-24	1,102	
VMMC_CIRC_DSD	By Age: 25-49	850	
VMMC_CIRC_DSD	By Age: 50+	170	
VMMC_CIRC_DSD	Sum of age disaggregates	5,000	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,890	
HTC_TST_DSD	By Test Result: Negative	22,401	
HTC_TST_DSD	By Test Result: Positive	2,489	
HTC_TST_DSD	Sum of Test Result disaggregates	24,890	
HTC_TST_DSD	Age/sex: 10-14 Male	7,467	
HTC_TST_DSD	Age/sex: 15-19 Male	6,969	
HTC_TST_DSD	Age/sex: 20-24 Male	5,476	
HTC_TST_DSD	Age/sex: 25-49 Male	4,231	
HTC_TST_DSD	Age/sex: 50+ Male	747	
HTC_TST_DSD	Sum of Age/Sex disaggregates	24,890	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,467	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,423	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	7,467	



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,423	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	24,890	

### Implementing Mechanism Details

<b>Mechanism ID: 10427</b>	<b>Mechanism Name: Malawi Blood Transfusion Service</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Malawi Blood Transfusion Service	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 1,000,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 10427</b>
----------------------------



<b>Mechanism Name:</b>	<b>Malawi Blood Transfusion Service</b>		
<b>Prime Partner Name:</b>	<b>Malawi Blood Transfusion Service</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	1,000,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11453</b>	<b>Mechanism Name: Peace Corps Volunteers</b>
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 407,454</b>	
<b>Applied Pipeline Amount: 69,752</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	407,454

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	62,500
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 11453			
<b>Mechanism Name:</b> Peace Corps Volunteers			
<b>Prime Partner Name:</b> U.S. Peace Corps			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	120,555	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	286,899	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,000	
OVC_SERV_DSD	Sex: Male	1,000	
OVC_SERV_DSD	Sex: Female	3,000	
OVC_SERV_DSD	Sum of Sex disaggregates	4,000	
OVC_SERV_DSD	Age: 18+	4,000	
OVC_SERV_DSD	Sum of Age disaggregates	4,000	

## Implementing Mechanism Details

<b>Mechanism ID: 12105</b>	<b>Mechanism Name: Support for Health Systems Strengthening and HIV/AIDS Service Delivery in Malawi's South-East Zone</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Dignitas International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,421,350</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,421,350
GHP-USAID	0

## Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Human Resources for Health	3,732,810
Renovation	150,000
Food and Nutrition: Policy, Tools, and Service Delivery	76,303

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12105		
<b>Mechanism Name:</b>	Support for Health Systems Strengthening and HIV/AIDS Service Delivery in Malawi's South-East Zone		
<b>Prime Partner Name:</b>	Dignitas International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	558,688	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	208,688	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	322,197	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	839,125	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,092,652	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	15,597	14,984
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	17,146	16,707
PMTCT_ARV_DSD	Life-long ART (including Option B+)	15,597	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	7,798	6,702
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	7,799	7,330

PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	15,597	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	15,597	14,032
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	152,092	154,547
PMTCT_STAT_DSD	Number of new ANC and L&D clients	168,138	166,153
PMTCT_STAT_DSD	By: Known positives at entry	8,059	329
PMTCT_STAT_DSD	By: Number of new positives identified	9,087	402
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	17,146	731
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	368,511	
HTC_TST_DSD	By Test Result: Negative	331,660	
HTC_TST_DSD	By Test Result: Positive	36,851	
HTC_TST_DSD	Sum of Test Result disaggregates	368,511	
HTC_TST_DSD	Age/sex: 15-19 Male	31,323	
HTC_TST_DSD	Age/sex: 20-24 Male	31,323	
HTC_TST_DSD	Age/sex: 25-49 Male	56,383	
HTC_TST_DSD	Age/sex: 50+ Male	9,213	
HTC_TST_DSD	Age/sex: 15-19 Female	60,804	
HTC_TST_DSD	Age/sex: 20-24 Female	60,804	
HTC_TST_DSD	Age/sex: 25-49 Female	109,448	
HTC_TST_DSD	Age/sex: 50+ Female	9,213	
HTC_TST_DSD	Sum of Age/Sex disaggregates	368,511	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	128,242	

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	240,269	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	368,511	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	368,511	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	130,681	199,181
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	49,368	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	81,313	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	130,681	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	81,188	58,015
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	30,671	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	50,517	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	81,188	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	81,188	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,704	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,793	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	121,880	182,719



TX_CURR_DSD	Age/Sex: 15+ Male	42,658	
TX_CURR_DSD	Age/Sex: 15+ Female	79,222	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	42,658	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	79,222	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	121,880	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	121,880	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	0	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	35,084	52,242
TX_NEW_DSD	By Age/Sex: 15-19 Male	3,070	484
TX_NEW_DSD	By Age/Sex: 20-24 Male	3,070	761
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,526	14,515
TX_NEW_DSD	By Age/Sex: 50+ Male	877	2,484
TX_NEW_DSD	By Age/Sex: 15-19 Female	5,701	1,480
TX_NEW_DSD	By Age/Sex: 20-24 Female	5,701	5,270
TX_NEW_DSD	By Age/Sex: 25-49 Female	10,262	25,017
TX_NEW_DSD	By Age/Sex: 50+ Female	877	2,100
TX_NEW_DSD	Sum of Age/Sex disaggregates	35,084	52,111
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	12,543	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	22,541	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	35,084	
TX_NEW_DSD	Pregnancy status	8,456	10,412
TX_NEW_DSD	Breastfeeding status	2,105	2,843
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	28,769	42,964
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	35,084	53,276



LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	81	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	129,374	190,388
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	130,681	199,181

### Implementing Mechanism Details

<b>Mechanism ID: 12107</b>	<b>Mechanism Name: EQUIP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Partners in Hope	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,415,490</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,645,829
GHP-USAID	1,769,661

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,469,294
----------------------------	-----------



Renovation	100,000
Food and Nutrition: Policy, Tools, and Service Delivery	46,594
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12107		
<b>Mechanism Name:</b>	EQUIP		
<b>Prime Partner Name:</b>	Partners in Hope		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	360,630	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	210,630	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	210,630	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HVSI	0	0

Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	373,753	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	273,753	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,248,958	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	337,136	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,611	1,989
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,031	2,091
PMTCT_ARV_DSD	Life-long ART (including Option B+)	2,611	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,305	955
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current	1,306	1,033

	pregnancy		
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	2,611	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	2,611	1,988
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,199	48,938
PMTCT_STAT_DSD	Number of new ANC and L&D clients	63,020	51,513
PMTCT_STAT_DSD	By: Known positives at entry	1,425	939
PMTCT_STAT_DSD	By: Number of new positives identified	1,606	1,148
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,031	2,087
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	180,371	193,260
HTC_TST_DSD	By Test Result: Negative	162,334	186,304
HTC_TST_DSD	By Test Result: Positive	18,037	6,956
HTC_TST_DSD	Sum of Test Result disaggregates	180,371	193,260
HTC_TST_DSD	Age/sex: <1 Male	620	
HTC_TST_DSD	Age/sex: 1-4 Male	2,480	
HTC_TST_DSD	Age/sex: 5-9 Male	2,480	
HTC_TST_DSD	Age/sex: 10-14 Male	2,170	
HTC_TST_DSD	Age/sex: 15-19 Male	14,014	
HTC_TST_DSD	Age/sex: 20-24 Male	14,014	
HTC_TST_DSD	Age/sex: 25-49 Male	25,224	
HTC_TST_DSD	Age/sex: 50+ Male	4,122	
HTC_TST_DSD	Age/sex: <1 Female	620	
HTC_TST_DSD	Age/sex: 1-4 Female	2,480	
HTC_TST_DSD	Age/sex: 5-9 Female	2,480	
HTC_TST_DSD	Age/sex: 10-14 Female	2,170	
HTC_TST_DSD	Age/sex: 15-19 Female	27,204	
HTC_TST_DSD	Age/sex: 20-24 Female	27,204	
HTC_TST_DSD	Age/sex: 25-49 Female	48,967	
HTC_TST_DSD	Age/sex: 50+ Female	4,122	

HTC_TST_DSD	Sum of Age/Sex disaggregates	180,371	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,750	30,581
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	57,374	63,687
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,750	30,596
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	107,497	68,396
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,500	61,177
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	164,871	132,083
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	180,371	193,260
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0	
HTC_TST_TA	By Test Result: Negative	0	
HTC_TST_TA	By Test Result: Positive	0	
HTC_TST_TA	Sum of Test Result disaggregates	0	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	38,707	44,963
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,935	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	13,161	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,935	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	21,676	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	38,707	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the	22,183	6,686

	reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,109	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	7,543	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,109	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	12,422	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	22,183	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	22,183	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	559	952
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	588	1,021
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,516	1,673
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,031	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	41,311	43,654
TX_CURR_DSD	Age/Sex: <1 Male	84	38
TX_CURR_DSD	Age/Sex: 1-4 Male	755	339
TX_CURR_DSD	Age/Sex: 5-14 Male	838	1,733
TX_CURR_DSD	Age/Sex: 15+ Male	13,285	
TX_CURR_DSD	Age/Sex: <1 Female	84	42
TX_CURR_DSD	Age/Sex: 1-4 Female	755	369
TX_CURR_DSD	Age/Sex: 5-14 Female	838	1,715

TX_CURR_DSD	Age/Sex: 15+ Female	24,672	
TX_CURR_DSD	Sum of age/sex disaggregates	3,354	43,654
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	84	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	84	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,677	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,285	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,677	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	24,672	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,354	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	37,957	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	41,311	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	168	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,710	6,258
TX_NEW_DSD	By Age/Sex: <1 Male	34	83
TX_NEW_DSD	By Age/Sex: 1-4 Male	203	199
TX_NEW_DSD	By Age/Sex: 5-9 Male	68	160
TX_NEW_DSD	By Age/Sex: 10-14 Male	34	122
TX_NEW_DSD	By Age/Sex: 15-19 Male	878	41
TX_NEW_DSD	By Age/Sex: 20-24 Male	878	67
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,579	1,443
TX_NEW_DSD	By Age/Sex: 50+ Male	251	246
TX_NEW_DSD	By Age/Sex: <1 Female	34	89
TX_NEW_DSD	By Age/Sex: 1-4 Female	203	178
TX_NEW_DSD	By Age/Sex: 5-9 Female	68	136
TX_NEW_DSD	By Age/Sex: 10-14 Female	34	141
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,630	142
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,630	533
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,935	2,482
TX_NEW_DSD	By Age/Sex: 50+ Female	251	197
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,710	6,259

TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	34	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	339	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,586	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	34	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	339	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,446	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,710	
TX_NEW_DSD	Pregnancy status	2,249	1,362
TX_NEW_DSD	Breastfeeding status	643	373
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,782	5,007
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,710	6,257
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	6	
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	6	
LAB_ACC_DSD	Sum of Support Type disaggregates	6	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	45	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	45	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	45	



FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	36
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	45	41
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	38,320	44,065
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	38,707	44,963

### Implementing Mechanism Details

<b>Mechanism ID: 12109</b>	<b>Mechanism Name: USAID Tuberculosis CARE Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0
GHP-USAID	0

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 12109			
<b>Mechanism Name:</b> USAID Tuberculosis CARE Project			
<b>Prime Partner Name:</b> University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,775	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,775	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	103,309	

### Implementing Mechanism Details



<b>Mechanism ID: 12111</b>	<b>Mechanism Name: Supporting implementation of National AIDS Framework through improving coverage and quality of HIV and AIDS Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,239,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,239,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	120,000
---------------------------	---------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12111
<b>Mechanism Name:</b>	Supporting implementation of National AIDS Framework through improving coverage and quality of HIV and AIDS Services
<b>Prime Partner Name:</b>	Ministry of Health, Malawi



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	54,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	26,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	96,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	86,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	27,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	78,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	285,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	36,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,493,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	55,900	0

### Implementing Mechanism Indicator Information



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 12116</b>	<b>Mechanism Name: ASGF/State for Ambassadors Small Grant for HIV/AIDS</b>
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	<b>12116</b>
----------------------	--------------



<b>Mechanism Name:</b> ASGF/State for Ambassadors Small Grant for HIV/AIDS			
<b>Prime Partner Name:</b> U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	420	
PP_PREV_DSD	Total number of people in the target population	420	
PP_PREV_DSD	Age/sex: 10-14 Male	70	
PP_PREV_DSD	Age/sex: 15-19 Male	70	
PP_PREV_DSD	Age/sex: 20-24 Male	70	
PP_PREV_DSD	Age/sex: 10-14 Female	70	
PP_PREV_DSD	Age/sex: 15-19 Female	70	
PP_PREV_DSD	Age/sex: 20-24 Female	70	
PP_PREV_DSD	Sum of Age/Sex disaggregates	420	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	200	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	50	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ	50	



	PERMISSION ONLY: <15 Female		
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	50	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	100	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	100	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	200	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	700	

### Implementing Mechanism Details

<b>Mechanism ID: 12118</b>	<b>Mechanism Name: BLM CIRC GHAI</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Banja La Mtsogolo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0
GHP-USAID	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 12118			
<b>Mechanism Name:</b> BLM CIRC GHAI			
<b>Prime Partner Name:</b> Banja La Mtsogolo			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	16,129	
VMMC_CIRC_DSD	By Age: 10-14	4,796	
VMMC_CIRC_DSD	By Age: 15-19	4,491	
VMMC_CIRC_DSD	By Age: 20-24	3,558	
VMMC_CIRC_DSD	By Age: 25-49	2,742	
VMMC_CIRC_DSD	By Age: 50+	542	
VMMC_CIRC_DSD	Sum of age disaggregates	16,129	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	15,322	
HTC_TST_DSD	By Test Result: Negative	13,790	
HTC_TST_DSD	By Test Result: Positive	1,532	
HTC_TST_DSD	Sum of Test Result disaggregates	15,322	
HTC_TST_DSD	Age/sex: 10-14 Male	4,597	



HTC_TST_DSD	Age/sex: 15-19 Male	4,290	
HTC_TST_DSD	Age/sex: 20-24 Male	3,371	
HTC_TST_DSD	Age/sex: 25-49 Male	2,605	
HTC_TST_DSD	Age/sex: 50+ Male	459	
HTC_TST_DSD	Sum of Age/Sex disaggregates	15,322	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,597	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,725	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,597	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,725	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	15,322	

### Implementing Mechanism Details

<b>Mechanism ID: 12119</b>	<b>Mechanism Name: Building the Nursing Workforce and Nursing Training Capacity in Malawi</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Global AIDS Interfaith Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	12119		
<b>Mechanism Name:</b>	Building the Nursing Workforce and Nursing Training Capacity in		
<b>Prime Partner Name:</b>	Malawi		
<b>Prime Partner Name:</b>	Global AIDS Interfaith Alliance		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	91	
HRH_PRE	By Graduates: Nurses	91	
HRH_PRE	Sum of Graduates disaggregated	91	

### Implementing Mechanism Details

<b>Mechanism ID: 12126</b>	<b>Mechanism Name: Feed/OVC/GHAI</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Feed the Children	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12126			
<b>Mechanism Name:</b> Feed/OVC/GHAI			
<b>Prime Partner Name:</b> Feed the Children			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2015	2016
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	169,731	

### Implementing Mechanism Details

<b>Mechanism ID: 12130</b>	<b>Mechanism Name: Baylor College of Medicine</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,013,481</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,475,976
GHP-USAID	1,537,505

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	3,548,088
Construction	200,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Food and Nutrition: Policy, Tools, and Service Delivery	15,910



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 12130			
<b>Mechanism Name:</b> Baylor College of Medicine			
<b>Prime Partner Name:</b> Baylor College of Medicine Children's Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	106,065	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	219,112	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	918,533	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	179,408	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,036,564	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	2,653,799	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	753	692
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	849	728
PMTCT_ARV_DSD	Life-long ART (including Option B+)	753	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	377	332
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	376	360
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	753	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	753	692
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,429	12,179
PMTCT_STAT_DSD	Number of new ANC and L&D clients	13,468	12,820
PMTCT_STAT_DSD	By: Known positives at entry	399	327

PMTCT_STAT_DSD	By: Number of new positives identified	450	401
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	849	728
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	120,611	1,007,421
HTC_TST_DSD	By Test Result: Negative	12,061	940,085
HTC_TST_DSD	By Test Result: Positive	108,550	67,336
HTC_TST_DSD	Sum of Test Result disaggregates	120,611	1,007,421
HTC_TST_DSD	Age/sex: <1 Male	3,603	
HTC_TST_DSD	Age/sex: 1-4 Male	14,411	
HTC_TST_DSD	Age/sex: 5-9 Male	14,411	
HTC_TST_DSD	Age/sex: 10-14 Male	12,610	
HTC_TST_DSD	Age/sex: 15-19 Male	2,596	
HTC_TST_DSD	Age/sex: 20-24 Male	2,596	
HTC_TST_DSD	Age/sex: 25-49 Male	4,672	
HTC_TST_DSD	Age/sex: 50+ Male	764	
HTC_TST_DSD	Age/sex: <1 Female	3,603	
HTC_TST_DSD	Age/sex: 1-4 Female	14,411	
HTC_TST_DSD	Age/sex: 5-9 Female	14,411	
HTC_TST_DSD	Age/sex: 10-14 Female	12,610	
HTC_TST_DSD	Age/sex: 15-19 Female	5,039	
HTC_TST_DSD	Age/sex: 20-24 Female	5,039	
HTC_TST_DSD	Age/sex: 25-49 Female	9,071	
HTC_TST_DSD	Age/sex: 50+ Female	764	
HTC_TST_DSD	Sum of Age/Sex disaggregates	120,611	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	45,035	140,788
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,628	350,138
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	45,035	140,859
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,913	375,636

HTC_TST_DSD	Sum of Aggregated Age/Sex <15	90,070	281,647
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	30,541	725,774
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	120,611	1,007,421
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,683	29,592
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	8,205	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,503	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	8,205	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,770	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	25,683	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	15,628	7,915
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	5,092	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,057	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	5,092	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,387	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	15,628	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	15,628	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	9,544	584
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include	19,087	

	known HIV-positive women at entry into PMTCT)		
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,101	33,689
TX_CURR_DSD	Age/Sex: <1 Male	485	216
TX_CURR_DSD	Age/Sex: 1-4 Male	4,362	1,865
TX_CURR_DSD	Age/Sex: 5-14 Male	4,846	9,483
TX_CURR_DSD	Age/Sex: 15+ Male	2,700	
TX_CURR_DSD	Age/Sex: <1 Female	485	256
TX_CURR_DSD	Age/Sex: 1-4 Female	4,362	2,010
TX_CURR_DSD	Age/Sex: 5-14 Female	4,846	9,427
TX_CURR_DSD	Age/Sex: 15+ Female	5,015	
TX_CURR_DSD	Sum of age/sex disaggregates	19,386	33,689
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	485	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	485	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	9,693	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,700	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	9,693	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,015	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	19,386	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,715	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	27,101	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	970	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,013	8,869
TX_NEW_DSD	By Age/Sex: <1 Male	296	485
TX_NEW_DSD	By Age/Sex: 1-4 Male	1,776	1,107
TX_NEW_DSD	By Age/Sex: 5-9 Male	592	904
TX_NEW_DSD	By Age/Sex: 10-14 Male	296	690
TX_NEW_DSD	By Age/Sex: 15-19 Male	183	20
TX_NEW_DSD	By Age/Sex: 20-24 Male	183	32

TX_NEW_DSD	By Age/Sex: 25-49 Male	331	724
TX_NEW_DSD	By Age/Sex: 50+ Male	52	121
TX_NEW_DSD	By Age/Sex: <1 Female	296	518
TX_NEW_DSD	By Age/Sex: 1-4 Female	1,776	1,009
TX_NEW_DSD	By Age/Sex: 5-9 Female	592	780
TX_NEW_DSD	By Age/Sex: 10-14 Female	296	801
TX_NEW_DSD	By Age/Sex: 15-19 Female	340	70
TX_NEW_DSD	By Age/Sex: 20-24 Female	340	266
TX_NEW_DSD	By Age/Sex: 25-49 Female	612	1,243
TX_NEW_DSD	By Age/Sex: 50+ Female	52	99
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,013	8,869
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	296	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,960	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	749	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	296	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,960	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,344	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	8,013	
TX_NEW_DSD	Pregnancy status	545	629
TX_NEW_DSD	Breastfeeding status	0	171
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	25,426	28,881
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,683	29,592

### Implementing Mechanism Details

<b>Mechanism ID: 12131</b>	<b>Mechanism Name: Christian Health Association</b>
----------------------------	---



	<b>of Malawi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,200,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,000,000
Motor Vehicles: Purchased	50,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 12131			
<b>Mechanism Name:</b> Christian Health Association of Malawi			
<b>Prime Partner Name:</b> Christian Health Association of Malawi			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,000,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS	Number of HIV-positive pregnant	2,452		Redacted

D	women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,581		Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	2,452		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,452		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	2,452		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	2,452		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,229		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	24,451		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	13,473		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	9,756		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	23,229		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	20,000	5,452	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	15,000	5,738	Redacted
PMTCT_STAT_TA	By: Known positives at entry	18,000	2,454	Redacted

PMTCT_STAT_TA	By: Number of new positives identified	2,000	2,998	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	20,000	5,452	Redacted
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	75		Redacted
VMMC_AE_DSD	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)	75		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)	50		Redacted
VMMC_AE_DSD	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	25		Redacted
VMMC_AE_DSD	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)	90		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)	75		Redacted
VMMC_AE_DSD	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)	15		Redacted
VMMC_CIRC_DS D	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV	5,000		Redacted

	prevention program within the reporting period			
VMMC_CIRC_DS D	By Age: <1	0		Redacted
VMMC_CIRC_DS D	By Age: 1-9	0		Redacted
VMMC_CIRC_DS D	By Age: 10-14	1,234		Redacted
VMMC_CIRC_DS D	By Age: 15-19	1,583		Redacted
VMMC_CIRC_DS D	By Age: 20-24	1,333		Redacted
VMMC_CIRC_DS D	By Age: 25-49	600		Redacted
VMMC_CIRC_DS D	By Age: 50+	250		Redacted
VMMC_CIRC_DS D	Sum of age disaggregates	5,000		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	500		Redacted
VMMC_CIRC_DS D	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	4,500		Redacted
VMMC_CIRC_DS D	By circumcision technique: Surgical VMMC	5,000		Redacted
VMMC_CIRC_DS D	By circumcision technique: Device-based VMMC	0		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	3,250		Redacted
VMMC_CIRC_DS D	By follow-up status: Number of surgically circumcised clients who did	1,750		Redacted

	NOT return for follow-up care within 14 days of circumcision surgery			
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	8,334		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,667		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	104,477		Redacted
HTC_TST_DSD	By Test Result: Negative	9,370		Redacted
HTC_TST_DSD	By Test Result: Positive	10,726		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	20,096		Redacted
HTC_TST_DSD	Age/sex: <1 Male	629		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,517		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	2,455		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	2,091		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	5,742		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,774		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	13,624		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	4,369		Redacted
HTC_TST_DSD	Age/sex: <1 Female	611		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,445		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,484		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	2,156		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	11,868		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	9,969		Redacted

HTC_TST_DSD	Age/sex: 25-49 Female	28,792		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	9,951		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	104,477		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,693		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,508		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,697		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	60,579		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,390		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	89,087		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	104,477		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	45,703		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	161		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	644		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	628		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	535		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	2,860		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	2,378		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	6,786		Redacted

CARE_CURR_DS D	Age/sex: 50+ Male	2,176		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	156		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	626		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	635		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	552		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	5,400		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	4,536		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	13,102		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	4,528		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	45,703		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,608		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,992		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,992		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,408		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	20,000		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at	10,190		Redacted

	enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Age/sex: <1 Male	54		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	216		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	210		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	179		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	607		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	505		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,441		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	462		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	52		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	210		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	213		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	185		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	1,147		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	963		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	2,783		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	962		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	10,189		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	605		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	3,994		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	660		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	5,855		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	11,114		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	11,114		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,169		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive	3,330		Redacted

	women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,490		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,490		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	679		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	45,704		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	161		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	644		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,163		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	14,201		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	156		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	626		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,187		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	27,566		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	3,937		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	307		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	332		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	12,669		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,582		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	10,859		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,657		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	23,528		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	18,239		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	41,767		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	639		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,190		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	54		Redacted

TX_NEW_DSD	By Age/Sex: 1-4 Male	216		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	210		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	179		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	607		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	505		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,441		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	462		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	52		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	210		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	213		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	185		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,147		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	963		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,783		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	962		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,189		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	54		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	659		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,016		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	52		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	660		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,855		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,190		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,007		Redacted
TX_RET_DSD	Total number of adults and children	10,190		Redacted

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up			
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	360		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,093		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,741		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,194		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,093		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	3,741		Redacted

	stopped ART, and those lost to follow-up)			
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	3		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	3		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	3		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	6		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	18		Redacted
LAB_CAP_DSD	By clinical laboratories	18		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	18		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	18		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	18		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	66		Redacted
HRH_PRE	By Graduates: Nurses	66		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	66		Redacted
HRH_PRE	By new graduates who are licensed	66		Redacted



	and registered: Nurses			
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	43,300		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	45,703		Redacted
TB_SCREEN_DSD	Age: <1	1,000		Redacted
TB_SCREEN_DSD	Age: 1-4	2,400		Redacted
TB_SCREEN_DSD	Age: 5-9	3,600		Redacted
TB_SCREEN_DSD	Age: 10-14	2,600		Redacted
TB_SCREEN_DSD	Age: 15-19	4,000		Redacted
TB_SCREEN_DSD	Age: 20-24	3,000		Redacted
TB_SCREEN_DSD	Age: 25-49	2,400		Redacted
TB_SCREEN_DSD	Age: 50+	1,000		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	13,600		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	9,600		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	10,400		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	20,000		Redacted
TB_SCREEN_DSD	Sex: Male	9,600		Redacted
TB_SCREEN_DSD	Sex: Female	10,400		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	20,000		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 12638</b>	<b>Mechanism Name: Support for Service Delivery-Excellence</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,098,850</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	200,000
GHP-USAID	4,898,850

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	2,939,310
Food and Nutrition: Policy, Tools, and Service Delivery	46,594
Renovation	100,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12638		
<b>Mechanism Name:</b>	Support for Service Delivery-Excellence		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	500,747	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	250,747	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,747	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	367,165	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	367,165	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,585,026	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	377,253	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
------------------	-------	------	------

PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	4,322	4,704
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,895	4,951
PMTCT_ARV_DSD	Life-long ART (including Option B+)	4,322	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	2,161	2,260
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,161	2,444
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	4,322	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	4,322	4,704
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,826	58,195
PMTCT_STAT_DSD	Number of new ANC and L&D clients	54,712	61,258
PMTCT_STAT_DSD	By: Known positives at entry	2,301	3,387
PMTCT_STAT_DSD	By: Number of new positives identified	2,594	3,596
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,895	6,983
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	164,648	337,985
HTC_TST_DSD	By Test Result: Negative	148,183	318,101
HTC_TST_DSD	By Test Result: Positive	16,465	19,884
HTC_TST_DSD	Sum of Test Result disaggregates	164,648	337,985
HTC_TST_DSD	Age/sex: <1 Male	790	
HTC_TST_DSD	Age/sex: 1-4 Male	3,160	
HTC_TST_DSD	Age/sex: 5-9 Male	3,160	
HTC_TST_DSD	Age/sex: 10-14 Male	2,765	
HTC_TST_DSD	Age/sex: 15-19 Male	12,317	

HTC_TST_DSD	Age/sex: 20-24 Male	12,317	
HTC_TST_DSD	Age/sex: 25-49 Male	22,164	
HTC_TST_DSD	Age/sex: 50+ Male	3,623	
HTC_TST_DSD	Age/sex: <1 Female	790	
HTC_TST_DSD	Age/sex: 1-4 Female	3,160	
HTC_TST_DSD	Age/sex: 5-9 Female	3,160	
HTC_TST_DSD	Age/sex: 10-14 Female	2,765	
HTC_TST_DSD	Age/sex: 15-19 Female	23,909	
HTC_TST_DSD	Age/sex: 20-24 Female	23,909	
HTC_TST_DSD	Age/sex: 25-49 Female	43,036	
HTC_TST_DSD	Age/sex: 50+ Female	3,623	
HTC_TST_DSD	Sum of Age/Sex disaggregates	164,648	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,875	45,241
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	50,421	119,367
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,875	45,257
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	94,477	128,120
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	19,750	90,498
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	144,898	247,487
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	164,648	337,985
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	47,540	66,642
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,377	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,163	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ	2,377	

	PERMISSION ONLY: <15 Female		
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	26,623	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	47,540	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	28,343	19,127
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,417	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	9,637	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,417	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	15,872	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	28,343	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	28,343	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,447	3,961
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	4,895	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	47,994	63,925
TX_CURR_DSD	Age/Sex: <1 Male	130	54
TX_CURR_DSD	Age/Sex: 1-4 Male	1,170	483
TX_CURR_DSD	Age/Sex: 5-14 Male	1,300	2,472
TX_CURR_DSD	Age/Sex: 15+ Male	14,977	
TX_CURR_DSD	Age/Sex: <1 Female	130	65
TX_CURR_DSD	Age/Sex: 1-4 Female	1,170	524
TX_CURR_DSD	Age/Sex: 5-14 Female	1,300	2,446
TX_CURR_DSD	Age/Sex: 15+ Female	27,817	

TX_CURR_DSD	Sum of age/sex disaggregates	5,200	63,925
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	130	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	130	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,600	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,977	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,600	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	27,817	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,200	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	42,794	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	47,994	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	260	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,730	17,896
TX_NEW_DSD	By Age/Sex: <1 Male	69	142
TX_NEW_DSD	By Age/Sex: 1-4 Male	413	346
TX_NEW_DSD	By Age/Sex: 5-9 Male	138	276
TX_NEW_DSD	By Age/Sex: 10-14 Male	69	212
TX_NEW_DSD	By Age/Sex: 15-19 Male	993	123
TX_NEW_DSD	By Age/Sex: 20-24 Male	993	219
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,787	4,529
TX_NEW_DSD	By Age/Sex: 50+ Male	284	753
TX_NEW_DSD	By Age/Sex: <1 Female	69	152
TX_NEW_DSD	By Age/Sex: 1-4 Female	413	308
TX_NEW_DSD	By Age/Sex: 5-9 Female	138	239
TX_NEW_DSD	By Age/Sex: 10-14 Female	69	247
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,845	431
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,845	1,633
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,321	7,669
TX_NEW_DSD	By Age/Sex: 50+ Female	284	617
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,730	17,896
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	69	



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	689	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,057	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	69	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	689	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,295	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,730	
TX_NEW_DSD	Pregnancy status	2,673	3,898
TX_NEW_DSD	Breastfeeding status	764	1,063
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	47,065	65,113
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	47,540	66,642

### Implementing Mechanism Details

<b>Mechanism ID: 13101</b>	<b>Mechanism Name: ASSIST (former Health Care Improvement) Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Food and Nutrition: Commodities	100,000
Economic Strengthening	100,000
Gender: Gender Equality	50,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Gender: GBV	50,000
Focus Area:	GBV Prevention
Human Resources for Health	100,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	13101		
<b>Mechanism Name:</b>	ASSIST (former Health Care Improvement) Project		
<b>Prime Partner Name:</b>	University Research Corporation, LLC		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14113</b>	<b>Mechanism Name: District Health System Strengthening and Quality Improvement for Service Delivery in Malawi under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,457,803</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,457,803

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	50,000
Key Populations: MSM and TG	50,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	14113		
<b>Mechanism Name:</b>	District Health System Strengthening and Quality Improvement for		
<b>Prime Partner Name:</b>	Service Delivery in Malawi under PEPFAR		
	Elizabeth Glaser Pediatric AIDS Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	323,185	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	183,764	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	45,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	85,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	75,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	684,670	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	345,106	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	2,361,048	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	354,230	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,849	4,585	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	4,181	4,829	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	3,849		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,924	2,180	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,925	2,369	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0	Redacted
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0	0	Redacted

PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	3,849	0	Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	3,849	4,549	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,150		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,300		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	2,150		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,380		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	770		Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	2,150		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	2,150		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	80,342	93,393	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	86,290	98,307	Redacted

PMTCT_STAT_DS D	By: Known positives at entry	1,965	2,168	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	2,216	2,654	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	4,181	4,822	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,000		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	75,440		Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,392		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	2,088		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,480		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	10,000		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,000		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	259,947	580,106	Redacted
HTC_TST_DSD	By Test Result: Negative	233,952	554,954	Redacted
HTC_TST_DSD	By Test Result: Positive	25,995	25,152	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	259,947	580,106	Redacted
HTC_TST_DSD	Age/sex: <1 Male	898		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,591		Redacted

HTC_TST_DSD	Age/sex: 5-9 Male	3,591		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	3,142		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	20,188		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	20,188		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	36,336		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,938		Redacted
HTC_TST_DSD	Age/sex: <1 Female	898		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	3,591		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	3,591		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	3,142		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	39,188		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	39,188		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	70,539		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,938		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	259,947		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,222	69,284	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	82,650	212,872	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,222	69,313	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	154,853	228,634	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	22,444	138,597	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	237,503	441,506	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	259,947	580,103	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	182,071		Redacted
HTC_TST_TA	By Test Result: Negative	171,147		Redacted
HTC_TST_TA	By Test Result: Positive	10,924		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	182,071		Redacted

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,245		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,135		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	53,939		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	120,752		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	56,184		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	125,887		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	182,071		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	51,124	88,531	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,556		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,382		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,556		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,630		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	51,124		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	23,414		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	641		Redacted

CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,433		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,239		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	14,101		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	23,414		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	29,663	24,190	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,483		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	10,086		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	1,483		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	16,611		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	29,663		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	29,663		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	784	1,712	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	825	1,846	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,091	3,858	Redacted

PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	4,181		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	120	1,430	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,080	2,428	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,200	3,858	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	120		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	53,653	86,220	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	110	69	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	990	627	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,099	3,179	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	17,239		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	110	88	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	990	674	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,099	3,160	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	32,016		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	4,398	86,220	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	110		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	110		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,199		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	17,239		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,199		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	32,016		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,398		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	49,255		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	53,653		Redacted

TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	220		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	23,414		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	641		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,433		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,239		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	14,101		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,880		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	21,534		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	23,414		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	13,290	22,637	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	49	229	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	296	547	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	99	447	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	49	332	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,077	148	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,077	253	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,935	5,514	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	308	916	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	49	251	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	296	486	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	99	378	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	49	392	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	2,000	535	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,000	2,017	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,599	9,435	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	308	757	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	13,290	22,637	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	49		Redacted

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	493		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,397		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	49		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	493		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,907		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	13,290		Redacted
TX_NEW_DSD	Pregnancy status	2,791	4,899	Redacted
TX_NEW_DSD	Breastfeeding status	797	1,338	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,898	18,110	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	13,290	22,637	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	20		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	16		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	4		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	20		Redacted



LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	20		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	16		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	4		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	20		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	50,613	86,761	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	51,124	88,531	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	23,414		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 14246</b>	<b>Mechanism Name: Abt Associates: HPSS</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 885,000</b>	
<b>Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	885,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	500,000
----------------------------	---------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14246		
<b>Mechanism Name:</b>	Abt Associates: HPSS		
<b>Prime Partner Name:</b>	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	885,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

**Implementing Mechanism Indicator Information**



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14432</b>	<b>Mechanism Name: support to MDF</b>
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14432		
<b>Mechanism Name:</b>	support to MDF		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>

Prevention	CIRC	0	0
------------	------	---	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	100	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,000	
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	0	
VMMC_CIRC_DSD	By Age: 10-14	2,527	
VMMC_CIRC_DSD	By Age: 15-19	1,228	
VMMC_CIRC_DSD	By Age: 20-24	516	
VMMC_CIRC_DSD	By Age: 25-49	696	
VMMC_CIRC_DSD	By Age: 50+	33	
VMMC_CIRC_DSD	Sum of age disaggregates	5,000	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,750	
HTC_TST_DSD	By Test Result: Negative	4,275	
HTC_TST_DSD	By Test Result: Positive	475	
HTC_TST_DSD	Sum of Test Result disaggregates	4,750	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,425	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,325	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,425	



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,325	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,750	

### Implementing Mechanism Details

<b>Mechanism ID: 14441</b>	<b>Mechanism Name: Lighthouse</b>		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Lighthouse			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: Yes	Managing Agency: HHS/CDC		

<b>Total All Funding Sources: 2,917,316</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,917,316

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	120,000
Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 14441			
<b>Mechanism Name:</b> Lighthouse			
<b>Prime Partner Name:</b> Lighthouse			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	510,409	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	55,132	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	7,150	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	23,150	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	65,190	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	283,692	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	65,144	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,793,921	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	113,528	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,259	2,975	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,389	3,132	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	3,259		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,630	1,403	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	1,629	1,521	Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	3,259		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	3,259	2,924	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	850		Redacted

PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	900		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	760		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	90		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	850		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,823	38,792	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	40,718	40,834	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	1,593	1,408	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	1,796	1,722	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	3,389	3,130	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,200		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	40,400		Redacted
PMTCT_STAT_TA	By: Known positives at entry	80		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	750		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	830		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	105,897	250,580	Redacted
HTC_TST_DSD	By Test Result: Negative	10,590	232,448	Redacted

HTC_TST_DSD	By Test Result: Positive	95,307	18,132	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	105,897	250,580	Redacted
HTC_TST_DSD	Age/sex: <1 Male	206		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	824		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	824		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	721		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	8,564		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	8,564		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	15,413		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	2,519		Redacted
HTC_TST_DSD	Age/sex: <1 Female	206		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	824		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	824		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	721		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	16,623		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	16,623		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	29,922		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	2,519		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	105,897		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,575	15,579	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	35,060	105,790	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,575	15,589	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	65,687	113,622	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,150	31,168	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	100,747	219,412	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	105,897	250,580	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their	96,000		Redacted

	test results during the past 12 months			
HTC_TST_TA	By Test Result: Negative	93,400		Redacted
HTC_TST_TA	By Test Result: Positive	2,600		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	96,000		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,400		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	31,200		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,500		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	61,900		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,900		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	93,100		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	96,000		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	32,769	58,279	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,252		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,433		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,252		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,832		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	32,769		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and	18,484	17,522	Redacted

	received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	673		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	6,475		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	673		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,663		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	18,484		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	18,484		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,495	1,889	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,573	2,031	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,149	2,505	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	2,297		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	35,603	54,639	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	29	16	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	264	137	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	293	701	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	12,050		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	29	20	Redacted

TX_CURR_DSD	Age/Sex: 1-4 Female	264	148	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	293	694	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	22,379		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,172	54,639	Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	22,379		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	29		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	29		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	587		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,050		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	587		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	22,379		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,174		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	34,429		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	35,603		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	58		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,110	16,320	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	19	53	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	116	127	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	39	101	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	19	78	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	763	117	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	763	199	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,374	4,400	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	218	733	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	19	57	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	116	111	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	39	88	Redacted

TX_NEW_DSD	By Age/Sex: 10-14 Female	19	89	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,418	428	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,418	1,613	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,552	7,528	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	218	598	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	9,110	16,320	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	19		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	193		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,118		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	19		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	193		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,606		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,110		Redacted
TX_NEW_DSD	Pregnancy status	1,963	3,555	Redacted
TX_NEW_DSD	Breastfeeding status	547	972	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,471	13,123	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,110	16,320	Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2		Redacted

FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	2		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	2		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	0		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	2		Redacted
FPINT_SITE_DSD	Service delivery type: Community	0		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	2		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	2		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	32,441	57,124	Redacted



TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	32,769	58,279	Redacted
---------------	---	--------	--------	----------

### Implementing Mechanism Details

Mechanism ID: 14442	<b>Mechanism Name: Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under PEPFAR</b>			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: BAOBAB Health Partnership				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
G2G: No	Managing Agency:			

<b>Total All Funding Sources: 2,900,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,900,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	80,000
---------------------------	--------

### Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 14442			
<b>Mechanism Name:</b> Improving Quality of Care and Health Impact through Sustainable, Integrated, Innovative Information System Technologies in Malawi under			
<b>Prime Partner Name:</b> PEPFAR			
BAOBAB Health Partnership			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	651,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	81,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	88,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	49,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	130,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,576,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	322,300	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning
------------------	-------	------	------	----------

				<b>Budget Targets</b>
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	11,942		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	13,180		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	11,942		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5,971		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	5,971		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	11,942		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	11,942		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	125,498		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	132,552		Redacted
PMTCT_STAT_TA	By: Known positives at entry	6,195		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	6,985		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	13,180		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	189,550		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,478		Redacted

CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	64,446		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,478		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	106,148		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	189,550		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	30,000		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	1,800		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	1,280		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	18,600		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,400		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	25,080		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	25,080		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	23,071		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	23,071		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	182,974		Redacted
TX_CURR_TA	Age/Sex: <1 Male	407		Redacted



TX_CURR_TA	Age/Sex: 1-4 Male	3,659		Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	4,065		Redacted
TX_CURR_TA	Age/Sex: 15+ Male	58,349		Redacted
TX_CURR_TA	Age/Sex: <1 Female	407		Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	3,659		Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	4,065		Redacted
TX_CURR_TA	Age/Sex: 15+ Female	108,363		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	16,262		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	407		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	407		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	8,131		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	58,349		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	8,131		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	108,363		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	16,262		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	166,712		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	182,974		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	814		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	189,550		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 14443</b>	<b>Mechanism Name: Strengthening District Health Planning and Strategic Information to Improve Maternal and Child Health</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14443		
<b>Mechanism Name:</b>	Strengthening District Health Planning and Strategic Information to		
<b>Prime Partner Name:</b>	Improve Maternal and Child Health		
<b>Prime Partner Name:</b>	United Nations Children's Fund		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	42,970		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	42,970		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	42,970		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	42,970		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 14448</b>	<b>Mechanism Name: SCMS</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,695,287</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,695,287

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 14448</b>			
<b>Mechanism Name: SCMS</b>			
<b>Prime Partner Name: Partnership for Supply Chain Management</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	6,695,287	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 15888</b>	<b>Mechanism Name: Strengthening the National OVC Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 800,000</b>	
<b>Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	64,880
GHP-USAID	735,120

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Economic Strengthening	125,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Education	125,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	125,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Construction	70,000
Human Resources for Health	100,000

### Key Issues



(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	15888		
<b>Mechanism Name:</b>	Strengthening the National OVC Program		
<b>Prime Partner Name:</b>	UNICEF		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	800,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16485</b>	<b>Mechanism Name: Integrated Adolescent Health Improvement Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Towwirane HIV/AIDS Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	0

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 16485			
<b>Mechanism Name:</b> Integrated Adolescent Health Improvement Program			
<b>Prime Partner Name:</b> Tovwirane HIV/AIDS Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 16486		<b>Mechanism Name:</b> ASPIRE	
Funding Agency: USAID		Procurement Type: Cooperative Agreement	
Prime Partner Name: Save The Children Federation Inc			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources:</b> 500,000	
<b>Applied Pipeline Amount:</b> 0	
Funding Source	Funding Amount



GHP-State	313,181
GHP-USAID	186,819

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Education	150,000
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	50,000
Water	50,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16486			
<b>Mechanism Name:</b> ASPIRE			
<b>Prime Partner Name:</b> Save The Children Federation Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	500,000	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 16678</b>	<b>Mechanism Name: District Health System Strengthening and Quality Improvement for Service Delivery in Malawi under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,752,376</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,752,376

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Key Populations: MSM and TG	250,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance



Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16678		
<b>Mechanism Name:</b>	District Health System Strengthening and Quality Improvement for Service Delivery in Malawi under PEPFAR		
<b>Prime Partner Name:</b>	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	229,464	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	345,462	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	391,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	68,600	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	66,400	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	939,376	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,289,423	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	1,964,956	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	456,895	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,169	9,192	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,415	9,674	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	9,169		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,585	4,413	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	4,584	4,779	Redacted
PMTCT_ARV_DS	Sum of Regimen Type disaggregates	9,169	0	Redacted

D				
PMTCT_ARV_DS D	Sum of New and Current disaggregates	9,169	9,192	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,218		Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,241		Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	9,218		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	5,623		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	3,597		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	9,218		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	9,220		Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	78,646	78,952	Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	84,074	83,105	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	4,895	4,353	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	5,520	5,322	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	10,415	9,675	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were	80,048		Redacted

	tested for HIV and received their results)			
PMTCT_STAT_TA	Number of new ANC and L&D clients	94,168		Redacted
PMTCT_STAT_TA	By: Known positives at entry	4,002		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	6,404		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	10,406		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	0		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG)	0		Redacted

	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)			
KP_PREV_DSD	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0		Redacted
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	246,249	509,326	Redacted
HTC_TST_DSD	By Test Result: Negative	24,625	465,919	Redacted
HTC_TST_DSD	By Test Result: Positive	221,624	43,407	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	246,249	509,326	Redacted
HTC_TST_DSD	Age/sex: <1 Male	1,721		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	6,884		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	6,884		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	6,024		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	17,274		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	17,274		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	31,092		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	5,081		Redacted
HTC_TST_DSD	Age/sex: <1 Female	1,721		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	6,884		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	6,884		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	6,024		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	33,532		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	33,532		Redacted

HTC_TST_DSD	Age/sex: 25-49 Female	60,357		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,081		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	246,249		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21,513	74,592	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	70,721	173,626	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21,513	74,637	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	132,502	186,471	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	43,026	149,229	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	203,223	360,097	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	246,249	509,326	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	449,280		Redacted
HTC_TST_TA	By Test Result: Negative	395,366		Redacted
HTC_TST_TA	By Test Result: Positive	53,914		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	449,280		Redacted
HTC_TST_TA	Age/sex: <1 Male	2,965		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	13,344		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	17,792		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	20,756		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	34,100		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	40,031		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	17,792		Redacted
HTC_TST_TA	Age/sex: 50+ Male	1,483		Redacted
HTC_TST_TA	Age/sex: <1 Female	6,020		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	27,092		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	36,122		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	42,142		Redacted

HTC_TST_TA	Age/sex: 15-19 Female	69,234		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	81,274		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	36,122		Redacted
HTC_TST_TA	Age/sex: 50+ Female	3,011		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	449,280		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	54,857		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	93,406		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	111,376		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	189,641		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	166,233		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	283,047		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	449,280		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	102,148	173,701	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,107		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	34,731		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,107		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	57,203		Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	102,148		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of	199,519		Redacted

	the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load			
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,708		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,404		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	69,867		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	110,540		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	199,519		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	55,015	41,755	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	2,751		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	18,704		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	2,751		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	30,809		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	55,015		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	55,015		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,544	2,169	Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented	1,626	2,339	Redacted

	HIV-positive status during TB treatment during the reporting period			
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,207	7,737	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	10,415		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	117,832	165,615	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	278	111	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	2,503	1,020	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	2,781	5,213	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	37,348		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	278	133	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	2,503	1,108	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	2,781	5,163	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	69,361		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	11,124	165,615	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	278		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	278		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,561		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	37,348		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,561		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	69,361		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	11,122		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	106,709		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	117,831		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	556		Redacted
TX_CURR_TA	Number of adults and children receiving	165,526		Redacted

	antiretroviral therapy (ART)			
TX_CURR_TA	Aggregated Age/Sex: <1 Male	1,233		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	2,250		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	4,273		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	54,241		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	7,805		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	99,207		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	12,078		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	153,448		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	165,526		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	3,483		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	25,251	39,066	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	166	235	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	995	563	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	332	450	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	166	340	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	1,919	265	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,919	459	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,455	10,134	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	548	1,663	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	166	253	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	995	497	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	332	385	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	166	397	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	3,564	986	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,564	3,718	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,416	17,347	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	548	1,374	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	25,251	39,066	Redacted

TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	166		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,659		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,841		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	166		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,659		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	14,092		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	25,251		Redacted
TX_NEW_DSD	Pregnancy status	5,303	8,510	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	20,706	31,251	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	25,251	39,066	Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	12		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	100		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	100		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform	17		Redacted

	clinical laboratory tests			
LAB_CAP_DSD	By clinical laboratories	12		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	5		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	17		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	17		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	101,127	170,220	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	102,148	173,701	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	199,519		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 16704</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 16716</b>	<b>Mechanism Name: STEPS</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Counterpart International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

<b>Total All Funding Sources: 1,200,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-USAID	1,200,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16716		
<b>Mechanism Name:</b>	STEPS		
<b>Prime Partner Name:</b>	Counterpart International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,000,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16794</b>	<b>Mechanism Name: MCHIP/SANKHANI</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 16794			
<b>Mechanism Name:</b> MCHIP/SANKHANI			
<b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)	369	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	18,441	
VMMC_CIRC_DSD	By Age: <1	0	
VMMC_CIRC_DSD	By Age: 1-9	0	
VMMC_CIRC_DSD	By Age: 10-14	5,484	
VMMC_CIRC_DSD	By Age: 15-19	5,135	
VMMC_CIRC_DSD	By Age: 20-24	4,068	
VMMC_CIRC_DSD	By Age: 25-49	3,136	
VMMC_CIRC_DSD	By Age: 50+	618	
VMMC_CIRC_DSD	Sum of age disaggregates	18,441	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	17,518	
HTC_TST_DSD	By Test Result: Negative	15,766	
HTC_TST_DSD	By Test Result: Positive	1,752	
HTC_TST_DSD	Sum of Test Result disaggregates	17,518	



HTC_TST_DSD	Age/sex: 10-14 Male	5,255	
HTC_TST_DSD	Age/sex: 15-19 Male	4,905	
HTC_TST_DSD	Age/sex: 20-24 Male	3,854	
HTC_TST_DSD	Age/sex: 25-49 Male	2,978	
HTC_TST_DSD	Age/sex: 50+ Male	526	
HTC_TST_DSD	Sum of Age/Sex disaggregates	17,518	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,255	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	12,263	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,255	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	12,263	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	17,518	

### Implementing Mechanism Details

<b>Mechanism ID: 17097</b>	<b>Mechanism Name: DOD Support to Malawi Defense Force HIV AIDS Program</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,520,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,520,000

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

Condom programming	50,000
Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 17097			
<b>Mechanism Name:</b> DOD Support to Malawi Defense Force HIV AIDS Program			
<b>Prime Partner Name:</b> Project Concern International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	50,000	0

Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	420,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	50,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	21	31
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including	23	32

	known HIV-positive at entry)		
PMTCT_ARV_DSD	Life-long ART (including Option B+)	21	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	11	15
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	10	16
PMTCT_ARV_DSD	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_DSD	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_DSD	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	21	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	21	31
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	0	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	602	617
PMTCT_STAT_DSD	Number of new ANC and L&D clients	640	649
PMTCT_STAT_DSD	By: Known positives at entry	11	
PMTCT_STAT_DSD	By: Number of new positives identified	12	
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	23	
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum	19,500	

	components during the reporting period.		
PP_PREV_TA	Total number of people in the target population	30,469	
PP_PREV_TA	Age/sex: 10-14 Male	1,234	
PP_PREV_TA	Age/sex: 15-19 Male	2,746	
PP_PREV_TA	Age/sex: 20-24 Male	2,318	
PP_PREV_TA	Age/sex: 25-49 Male	4,231	
PP_PREV_TA	Age/sex: 50+ Male	0	
PP_PREV_TA	Age/sex: 10-14 Female	1,050	
PP_PREV_TA	Age/sex: 15-19 Female	2,343	
PP_PREV_TA	Age/sex: 20-24 Female	1,970	
PP_PREV_TA	Age/sex: 25-49 Female	3,608	
PP_PREV_TA	Age/sex: 50+ Female	0	
PP_PREV_TA	Sum of Age/Sex disaggregates	19,500	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,497	20,642
HTC_TST_DSD	By Test Result: Negative	7,647	
HTC_TST_DSD	By Test Result: Positive	850	
HTC_TST_DSD	Sum of Test Result disaggregates	8,497	
HTC_TST_DSD	Age/sex: <1 Male	29	
HTC_TST_DSD	Age/sex: 1-4 Male	114	
HTC_TST_DSD	Age/sex: 5-9 Male	114	
HTC_TST_DSD	Age/sex: 10-14 Male	100	
HTC_TST_DSD	Age/sex: 15-19 Male	662	
HTC_TST_DSD	Age/sex: 20-24 Male	662	
HTC_TST_DSD	Age/sex: 25-49 Male	1,190	
HTC_TST_DSD	Age/sex: 50+ Male	195	
HTC_TST_DSD	Age/sex: <1 Female	29	
HTC_TST_DSD	Age/sex: 1-4 Female	114	
HTC_TST_DSD	Age/sex: 5-9 Female	114	
HTC_TST_DSD	Age/sex: 10-14 Female	100	

HTC_TST_DSD	Age/sex: 15-19 Female	1,284	
HTC_TST_DSD	Age/sex: 20-24 Female	1,284	
HTC_TST_DSD	Age/sex: 25-49 Female	2,311	
HTC_TST_DSD	Age/sex: 50+ Female	195	
HTC_TST_DSD	Sum of Age/Sex disaggregates	8,497	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	357	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,709	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	357	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,074	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	714	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	7,783	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	8,497	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,900	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,500	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,600	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,500	
HTC_TST_TA	Sum of Aggregated Age/Sex <15	3,500	
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	5,000	
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	8,500	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count	2,755	6,587

	OR viral load		
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	138	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	936	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	138	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,543	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,755	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	1,221	698
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	61	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	415	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	61	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	684	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	1,221	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	1,221	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,835	4,727
TX_CURR_DSD	Age/Sex: <1 Male	4	3
TX_CURR_DSD	Age/Sex: 1-4 Male	38	30
TX_CURR_DSD	Age/Sex: 5-14 Male	42	154
TX_CURR_DSD	Age/Sex: 15+ Male	1,283	
TX_CURR_DSD	Age/Sex: <1 Female	4	4
TX_CURR_DSD	Age/Sex: 1-4 Female	38	33
TX_CURR_DSD	Age/Sex: 5-14 Female	42	153
TX_CURR_DSD	Age/Sex: 15+ Female	2,383	
TX_CURR_DSD	Sum of age/sex disaggregates	168	4,727

TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	433	653
TX_NEW_DSD	By Age/Sex: <1 Male	2	15
TX_NEW_DSD	By Age/Sex: 1-4 Male	11	36
TX_NEW_DSD	By Age/Sex: 5-9 Male	4	29
TX_NEW_DSD	By Age/Sex: 10-14 Male	2	22
TX_NEW_DSD	By Age/Sex: 15-19 Male	35	3
TX_NEW_DSD	By Age/Sex: 20-24 Male	35	6
TX_NEW_DSD	By Age/Sex: 25-49 Male	61	127
TX_NEW_DSD	By Age/Sex: 50+ Male	10	21
TX_NEW_DSD	By Age/Sex: <1 Female	2	17
TX_NEW_DSD	By Age/Sex: 1-4 Female	11	32
TX_NEW_DSD	By Age/Sex: 5-9 Female	4	25
TX_NEW_DSD	By Age/Sex: 10-14 Female	2	26
TX_NEW_DSD	By Age/Sex: 15-19 Female	64	12
TX_NEW_DSD	By Age/Sex: 20-24 Female	64	47
TX_NEW_DSD	By Age/Sex: 25-49 Female	116	218
TX_NEW_DSD	By Age/Sex: 50+ Female	10	17
TX_NEW_DSD	Sum of Age/Sex disaggregates	433	653
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	19	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	141	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	19	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	254	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	433	
TX_NEW_DSD	Pregnancy status	11	142
TX_NEW_DSD	Breastfeeding status	6	39
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical	6	



	laboratory tests		
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	6	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	0	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	6	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,755	6,587

**Implementing Mechanism Details**

<b>Mechanism ID: 17268</b>	<b>Mechanism Name: Global HIV/AIDS Nursing Initiative</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b> 17268			
<b>Mechanism Name:</b> Global HIV/AIDS Nursing Initiative			
<b>Prime Partner Name:</b> Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	475		Redacted
HRH_PRE	By Graduates: Nurses	475		Redacted
HRH_PRE	Sum of Graduates disaggregated	475		Redacted
HRH_PRE	By new graduates who are licensed and registered: Nurses	475		Redacted

## Implementing Mechanism Details

<b>Mechanism ID:</b> 17341	<b>Mechanism Name:</b> Strengthening High Quality Laboratory Services Scale-Up for HIV Diagnosis,
----------------------------	---



<b>Care, Treatment and Monitoring in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,800,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,800,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	120,000
---------------------------	---------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17341
<b>Mechanism Name:</b>	Strengthening High Quality Laboratory Services Scale-Up for HIV
<b>Prime Partner Name:</b>	Diagnosis, Care, Treatment and Monitoring in Malawi under the President's Emergency Plan for AIDS Relief (PEPFAR)



University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets

PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	500		Redacted
PMTCT_STAT_DS D	Number of new ANC and L&D clients	500		Redacted
PMTCT_STAT_DS D	By: Known positives at entry	100		Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	400		Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	500		Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	500		Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	526		Redacted
PMTCT_STAT_TA	By: Known positives at entry	19		Redacted
PMTCT_STAT_TA	By: Number of new positives identified	21		Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	40		Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,000		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	200		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	200		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	300		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	300		Redacted
CARE_CURR_DS	Age/sex: 15-19 Male	2,000		Redacted

D				
CARE_CURR_DS D	Age/sex: 20-24 Male	3,000		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	3,000		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,000		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	300		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	300		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	450		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	450		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	3,000		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	4,500		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	4,500		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,500		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	25,000		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	189,550		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,478		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	64,446		Redacted

CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,478		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	106,148		Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	189,550		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	2,000		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	16		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	16		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	24		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	24		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	160		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	240		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	240		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	80		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	24		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	24		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	36		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	36		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	240		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	360		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	360		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	120		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	2,000		Redacted
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the	1,500		Redacted

	reporting period			
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,500		Redacted
TB_ART_DSD	Age: 0-4	60		Redacted
TB_ART_DSD	Age: 5-14	90		Redacted
TB_ART_DSD	Age: 15+	1,350		Redacted
TB_ART_DSD	Male	600		Redacted
TB_ART_DSD	Female	900		Redacted
TB_ART_DSD	Sum of Sex disaggregates	1,500		Redacted
TB_ART_DSD	Newly tested	1,000		Redacted
TB_ART_DSD	Known HIV-positive	500		Redacted
TB_ART_DSD	Sum of Test Status disaggregates	1,500		Redacted
TB_ART_DSD	Aggregated Age: <15	150		Redacted
TB_ART_DSD	Aggregated Age: 15+	1,350		Redacted
TB_ART_DSD	Sum of Aggregated Age disaggregates	1,500		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,528		Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	11,055		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,000		Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,528		Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,528		Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	442		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,500		Redacted

TX_CURR_DSD	Age/Sex: <1 Male	84		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	84		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	252		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	3,780		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	126		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	126		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	378		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	5,670		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,050		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	10		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	60		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	84		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	126		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	330		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,780		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	630		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,760		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	960		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,540		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,500		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	210		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	10,500		Redacted
TX_CURR_TA	Age/Sex: <1 Male	26		Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	236		Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	263		Redacted

TX_CURR_TA	Age/Sex: 15+ Male	3,570		Redacted
TX_CURR_TA	Age/Sex: <1 Female	26		Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	236		Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	263		Redacted
TX_CURR_TA	Age/Sex: 15+ Female	5,880		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	1,050		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	26		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	26		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	525		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	3,570		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	525		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,880		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,050		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	9,450		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	10,500		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	52		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,000		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	16		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	16		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	24		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	24		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	160		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	240		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	240		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	80		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	24		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	24		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	36		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	36		Redacted

TX_NEW_DSD	By Age/Sex: 15-19 Female	240		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	360		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	360		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	120		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,000		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	16		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	40		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	720		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	24		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	120		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,080		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,960		Redacted
TX_NEW_DSD	Pregnancy status	500		Redacted
TX_NEW_DSD	Breastfeeding status	50		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,500		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,000		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of	90		Redacted

	adults and children who are still alive and on treatment at 12 months after initiating ART)			
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,350		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	80		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	120		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,800		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	150		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,350		Redacted

TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,800		Redacted
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	15		Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	15		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	15		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	45		Redacted
LAB_CAP_DSD	By clinical laboratories	25		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	25		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	45		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	45		Redacted
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or	57		Redacted



	program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre			
HRH_PRE	By Graduates: Laboratory professionals	57		Redacted
HRH_PRE	Sum of Graduates disaggreagtes	57		Redacted
HRH_PRE	By new graduates who are licensed and registered: Laboratorians	57		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	23,000		Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	25,000		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	189,550		Redacted

### Implementing Mechanism Details

<b>Mechanism ID: 17451</b>	<b>Mechanism Name: Technical Assistance and Fellowship Program Partnership</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Universtiy of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,975,385</b>	
<b>Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	3,975,385

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	110,000
Human Resources for Health	1,018,100

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17451		
<b>Mechanism Name:</b>	Technical Assistance and Fellowship Program Partnership		
<b>Prime Partner Name:</b>	Universtiy of Washington		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,018,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	436,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,520,885	0

### Implementing Mechanism Indicator Information



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17480</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 17487</b>	<b>Mechanism Name: Strengthening Malawi's Vital Statistics Systems through Civil Registration under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Registration Bureau Malawi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 400,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	200,000
---------------------------	---------



## Key Issues

(No data provided.)

## Budget Code Information

<b>Mechanism ID:</b>	17487		
<b>Mechanism Name:</b>	Strengthening Malawi's Vital Statistics Systems through Civil		
<b>Prime Partner Name:</b>	Registration under PEPFAR National Registration Bureau Malawi		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 17488</b>	<b>Mechanism Name: Improving Medical Education in Malawi</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Malawi College of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 760,000</b>	
<b>Applied Pipeline Amount: 0</b>	
Funding Source	Funding Amount
GHP-State	760,000



**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Education	100,000
-----------	---------

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17488		
<b>Mechanism Name:</b>	Improving Medical Education in Malawi		
<b>Prime Partner Name:</b>	University of Malawi College of Medicine		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	9,600	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	5,500	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	50,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	350,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	9,700	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	MTCT	9,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	310,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	15,400	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17585</b>	<b>Mechanism Name: Linkages</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,210,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,210,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Gender: GBV	67,676
Focus Area:	GBV Prevention

Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	68,676
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Condom programming	400,000
Key Populations: MSM and TG	800,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	800,000
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17585		
<b>Mechanism Name:</b>	Linkages		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	541,450	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	508,300	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	508,300	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	110,500	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	541,450	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	1,085	
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	1,143	
PMTCT_ARV_DSD	Life-long ART (including Option B+)	1,085	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	543	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	542	
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	1,085	
PMTCT_ARV_DSD	Sum of New and Current disaggregates	1,085	
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,633	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,814	
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	13,739	13,740
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key	7,776	7,776

	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)		
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,963	5,964
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,739	15,788
HTC_TST_DSD	By Test Result: Negative	6,870	7,921
HTC_TST_DSD	By Test Result: Positive	6,869	7,867
HTC_TST_DSD	Sum of Test Result disaggregates	13,739	15,788
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	443	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,152	5,367
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	614	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,530	10,421
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,057	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	12,682	15,788
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	13,739	15,788
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,020	



CARE_NEW_DSD	Aggregated Age/sex: <15 Male	301	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,047	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	301	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,371	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,020	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	6,020	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,337	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	32	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	317	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,155	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	32	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	317	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,548	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,337	
TX_NEW_DSD	Pregnancy status	1,267	
TX_NEW_DSD	Breastfeeding status	380	

### Implementing Mechanism Details

<b>Mechanism ID: 17590</b>	<b>Mechanism Name: Project SOAR</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 372,248</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	372,248
-----------	---------

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Monitoring and Evaluation
Gender: GBV	100,000
Focus Area:	GBV Prevention
Education	50,000
Economic Strengthening	50,000
Condom programming	100,000
Water	25,000
Human Resources for Health	25,000
Food and Nutrition: Policy, Tools, and Service Delivery	50,000

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17590			
<b>Mechanism Name:</b> Project SOAR			
<b>Prime Partner Name:</b> Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	372,248	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 17594</b>	<b>Mechanism Name: SIFPO</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 600,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	600,000

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Gender: GBV	250,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	200,000
Gender: Gender Equality	150,000
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17594		
<b>Mechanism Name:</b>	SIFPO		
<b>Prime Partner Name:</b>	Population Services International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	244,607	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	55,393	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention	2,500	16,837

	intervention including the minimum components during the reporting period.		
PP_PREV_DSD	Total number of people in the target population	3,906	1,643,469
PP_PREV_DSD	Age/sex: 10-14 Male	22	
PP_PREV_DSD	Age/sex: 15-19 Male	289	3,500
PP_PREV_DSD	Age/sex: 20-24 Male	403	3,500
PP_PREV_DSD	Age/sex: 25-49 Male	522	
PP_PREV_DSD	Age/sex: 50+ Male	89	
PP_PREV_DSD	Age/sex: 10-14 Female	20	
PP_PREV_DSD	Age/sex: 15-19 Female	199	4,918
PP_PREV_DSD	Age/sex: 20-24 Female	383	4,919
PP_PREV_DSD	Age/sex: 25-49 Female	479	
PP_PREV_DSD	Age/sex: 50+ Female	94	
PP_PREV_DSD	Sum of Age/Sex disaggregates	2,500	16,837
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,615	79,556
HTC_TST_DSD	By Test Result: Negative	1,362	66,008
HTC_TST_DSD	By Test Result: Positive	12,253	13,548
HTC_TST_DSD	Sum of Test Result disaggregates	13,615	79,556
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	439	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,115	36,261
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	609	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,452	43,295
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,048	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	12,567	79,556
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	13,615	79,556
CARE_NEW_DSD	Number of HIV-infected adults and children	721	2,429



	newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	36	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	245	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	38	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	402	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	721	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	721	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	288	1,246
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	1	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	8	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	77	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	15	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	188	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	288	
TX_NEW_DSD	Pregnancy status	90	83
TX_NEW_DSD	Breastfeeding status	11	83
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	278	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	278	

### Implementing Mechanism Details

<b>Mechanism ID: 17720</b>	<b>Mechanism Name: Military Electronic Health</b>
----------------------------	---



	<b>Information Network</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: VISTA PARTNERS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 150,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17720		
<b>Mechanism Name:</b>	Military Electronic Health Information Network		
<b>Prime Partner Name:</b>	VISTA PARTNERS		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	150,000	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 18005</b>	<b>Mechanism Name: TB Challenge</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,853,023</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,853,023
GHP-USAID	0

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,711,814
Renovation	200,000

## Key Issues

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 18005			
<b>Mechanism Name:</b> TB Challenge			
<b>Prime Partner Name:</b> KNCV Tuberculosis Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,753,023	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18024</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18025</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18028</b>	<b>Mechanism Name: World Learning Malawi Scholarship Program</b>
----------------------------	--



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: World Learning	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------

### Key Issues

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 18028</b>			
<b>Mechanism Name: World Learning Malawi Scholarship Program</b>			
<b>Prime Partner Name: World Learning</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	500,000	0



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

<b>Mechanism ID: 18045</b>	<b>Mechanism Name: Bringing VMMC Services to Scale in the MDF</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 450,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	450,000

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	41,000
---------------------------	--------

## Key Issues

(No data provided.)

## Budget Code Information



<b>Mechanism ID: 18045</b>			
<b>Mechanism Name: Bringing VMMC Services to Scale in the MDF</b>			
<b>Prime Partner Name: JHPIEGO</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	450,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18063</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18125</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18142</b>	<b>Mechanism Name: SIFPO 2</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Marie Stopes International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	



Funding Source	Funding Amount
GHP-State	0

**Sub Partner Name(s)**

(No data provided.)

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Key Issues**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18142			
<b>Mechanism Name:</b> SIFPO 2			
<b>Prime Partner Name:</b> Marie Stopes International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		2,736	42,868	45,604	0
ICASS		26,411	413,766	440,177	0
Management Meetings/Professional Development		45,450	712,045	757,495	0
Non-ICASS Administrative Costs		42,477	199,561	242,038	0
Staff Program Travel		17,251	270,273	287,524	0
USG Staff Salaries and Benefits		193,630	3,033,532	3,227,162	0
<b>Total</b>	<b>0</b>	<b>327,955</b>	<b>4,672,045</b>	<b>5,000,000</b>	<b>0</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		5,000		5,000	0
ICASS		30,000		30,000	0
Management Meetings/Professional Development		5,000		5,000	0



Non-ICASS Administrative Costs		10,000		10,000	0
Staff Program Travel		30,000		30,000	0
USG Staff Salaries and Benefits		100,000		100,000	0
<b>Total</b>	<b>0</b>	<b>180,000</b>	<b>0</b>	<b>180,000</b>	<b>0</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing	211,100			211,100	0
Computers/IT Services		131,800		131,800	0
ICASS	1,192,400			1,192,400	0
Management Meetings/Professio nal Development		104,640		104,640	0
Non-ICASS Administrative Costs	109,000			109,000	0
Staff Program Travel	0	218,840		218,840	0
USG Renovation		231,000		231,000	0
USG Staff Salaries and Benefits	0	2,601,220		2,601,220	0
<b>Total</b>	<b>1,512,500</b>	<b>3,287,500</b>	<b>0</b>	<b>4,800,000</b>	<b>0</b>

### U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		13,800		13,800	0
ICASS		75,000		75,000	0
Indirect Costs		3,000		3,000	0
Management Meetings/Professional Development		14,000		14,000	0
Non-ICASS Administrative Costs		56,000		56,000	0
Non-ICASS Motor Vehicles		21,000		21,000	0
Staff Program Travel		48,200		48,200	0
USG Staff Salaries and Benefits		97,950		97,950	0
<b>Total</b>	<b>0</b>	<b>328,950</b>	<b>0</b>	<b>328,950</b>	<b>0</b>

### U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Institutional Contractors				0	0
Non-ICASS Administrative Costs		347,457		347,457	0



Peace Corps Volunteer Costs		371,174		371,174	304,527
Staff Program Travel		62,172		62,172	0
USG Staff Salaries and Benefits		171,191		171,191	0
<b>Total</b>	<b>0</b>	<b>951,994</b>	<b>0</b>	<b>951,994</b>	<b>304,527</b>